



PCT/GB04/003096
GB 04/03096



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 10 SEP 2004

WIPO

PCT


PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

L. Mahoney

Dated 23 August 2004

Request for grant of a patent

See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



1. Your reference	DUNY / P28698GB		
2. Patent application number (The Patent Office will fill in this part)	0316725.1	17JUL03 E823337-5 D02866 P01/7700 0.00-0316725.1	
3. Full name, address and postcode of the or of each applicant (underline all surnames)	University of Dundee 11 Perth Road Dundee DD1 4HN United Kingdom Patents ADP number (if you know it) 7822760001 If the applicant is a corporate body, give the country/state of its incorporation United Kingdom		
4. Title of the invention	METHODS		
5. Name of your agent (if you have one)	ERIC POTTER CLARKSON PARK VIEW HOUSE 58 THE ROPEWALK NOTTINGHAM NG1 5DD		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) Patents ADP number (if you know it)	1305010		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	YES		
a) any applicant named in part 3 is not an inventor; or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	111
Claims(s)	4
Abstract	1
Drawing(s)	20 + 20

10. If you are also filing in any of the following, state how many against each item.

Priority Documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (<i>Patents Form 7/77</i>)	NO
Request for preliminary examination and search (<i>Patents Form 9/77</i>)	NO
Request for substantive examination (<i>Patents Form 10/77</i>)	NO
Any other documents (please specify)	

11. I/We request the grant of a patent on the basis of this application.

Signature

ERIC POTTER CLARKSON

Date

16 July 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

0115 9552211

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

METHODS

The present invention relates to protein kinases and their regulation.

LKB1 is a Ser/Thr protein kinase not closely related to other protein kinases
5 (reviewed in (Yoo et al., 2002)). Mutations in LKB1 have been linked to
Peutz Jeghers Cancer Syndrome (PJS), an autosomal dominant inherited
disorder (Hemminki et al., 1998; Jenne et al., 1998) characterised in those
affected by the development multiple gastro-intestinal hamartomatous
polyps as well as a wide spectrum of benign and malignant tumours
10 (Hemminki, 1999), with a 15-fold increased risk of developing malignant
cancers in many tissues [20,21]. To date, nearly 100 different mutations in
the LKB1 gene have been identified in PJS patients, most of which would
be expected to impair the activity of LKB1 [22]. Deletion of both alleles of
the LKB1 gene in mice results in embryonic lethality at midgestation
15 arising from multiple defects (Ylikorkala et al., 2001), indicating that LKB1
plays an essential role in development. Importantly LKB1 heterozygous
mice are viable but develop a PJS-like disease characterised by gastro-
intestinal hamartomas, although it is controversial whether these are caused
by haploinsufficiency or loss of heterozygosity (reviewed in [22]). Later on
20 in life (for example over 50 weeks of age) these animals also develop
malignant tumours, such as hepatocellular carcinoma which were shown to
be associated with loss of LKB1 expression (Bardeesy et al., 2002; Jishage
et al., 2002; Miyoshi et al., 2002; Nakau et al., 2002; Rossi et al., 2002).
Overexpression of LKB1 in certain cancer cells results in growth
25 suppression due to a G1-cell cycle arrest which is dependent on LKB1
catalytic activity (Tiainen et al., 1999) and this has been proposed to be
mediated through activation of p21^{WAF1/CIP1} through a p53-dependent

mechanism (Tiainen et al., 2002). Taken together, these findings strongly indicate that LKB1 is likely to function as a tumour suppressor. Recent work has indicated that both the *C. elegans* (Watts et al., 2000) and the *Drosophila* (Martin and St Johnston, 2003) homologues of LKB1 regulate cell polarity and, if this function is conserved in humans, loss of cell polarity in PJS patients could account for the development of hamartomas. Although LKB1 is essentially nuclear when overexpressed in cells, a low level of cytosolic localisation is also frequently observed (Karuman et al., 2001; Smith et al., 1999; Tiainen et al., 1999). Significantly, mutants of LKB1 that are excluded from the nucleus retain full growth suppression activity, suggesting that the cytoplasmic localisation of this enzyme is important for its tumour suppressor function (Tiainen et al., 2002). Several mutant forms of LKB1 found in PJS patients localise only in the nucleus and are not detectable in the cytoplasm (Boudeau et al., 2003b; Tiainen et al., 2002), further suggesting that cytoplasmic localisation of LKB1 is important.

Relatively little is known about how LKB1 is regulated and how it functions. LKB1 is phosphorylated at multiple residues in vivo and mutation of certain phosphorylation sites hinders the ability of LKB1 to suppress cell growth, but the mechanisms by which these phosphorylation events regulate LKB1 function have not yet been defined (Collins et al., 2000; Sapkota et al., 2002a; Sapkota et al., 2002b; Sapkota et al., 2001). There has also been considerable interest in identifying LKB1-interacting proteins, which may regulate its function. To date, a number of proteins have been shown to bind LKB1, namely the p53 tumour suppressor protein (Karuman et al., 2001), the brahma-related gene 1 protein (Brg1), which is a

component of chromatin remodelling complexes (Marignani et al., 2001), a protein termed LKB1 interacting protein-1 (LIP1) (Smith et al., 2001) and the kinase-specific chaperone complex consisting of Cdc37 and Hsp90 (Boudeau et al., 2003a). The binding of LKB1 to p53 was proposed to be essential for mediating p53-dependent cell death (Karuman et al., 2001), whereas the binding of LKB1 to Brg1 was suggested to be required for Brg1-dependent cell growth arrest (Marignani et al., 2001). The interaction of LKB1 with LIP1 anchored LKB1 in the cytoplasm (Smith et al., 2001), while the binding of LKB1 to Cdc37 and Hsp90 stabilised the LKB1 protein in cells (Boudeau et al., 2003a).

Recently, we have shown that LKB1 is associated with a STE20-related pseudokinase termed STRAD α (STe20-Related ADaptor protein- α), which lacks catalytic activity because key residues required for the function of nearly all protein kinases are missing (Baas et al., 2003). Moreover, LKB1 binds STRAD α through its catalytic domain and this interaction enhances LKB1 *in vivo* activity as well as promoting LKB1 cytoplasmic localisation (Baas et al., 2003). LKB1 is no longer able to suppress cell growth in cells in which STRAD α has been depleted using an siRNA approach, suggesting that the binding of LKB1 to STRAD α plays an important role in mediating its tumour suppressor function. STRAD α is also phosphorylated *in vitro* and *in vivo* by LKB1, making STRAD α the first physiological substrate for LKB1 identified thus far (Baas et al., 2003).

AMP-activated protein kinase kinase (AMPKK) and AMP-activated protein kinase (AMPK) are the upstream and downstream components of a protein kinase cascade that acts as a sensor of cellular energy charge [1,2]. AMPK is activated by an elevation in cellular 5'-AMP that always accompanies a

fall in the ATP:ADP ratio due to the reaction catalysed by adenylate kinase ($2\text{ADP} \leftrightarrow \text{ATP} + \text{ADP}$). This occurs during metabolic stresses such as hypoxia, ischaemia, glucose deprivation and, in skeletal and cardiac muscle, during contraction or exercise [1-3]. Once activated by stress, AMPK
 5 switches on glucose and fatty acid uptake and oxidative metabolism of these fuels to generate ATP, while switching off biosynthetic pathways that consume ATP. It achieves this metabolic switching both by direct phosphorylation of metabolic enzymes and by longer-term effects on gene expression [1,2]. AMPK is also activated by metformin, one of the most
 10 widely used diabetes drugs (though required at high doses ie >2g per day in adults), by an unknown mechanism that does not involve lowering of cellular ATP levels. While AMPK is best known for its effects on metabolism, recent work suggests that it also regulates cell growth and proliferation. Firstly, activation of the kinase inhibits protein synthesis by
 15 causing phosphorylation of elongation factor-2 [4], and by inhibiting phosphorylation of p70S6K by the mTOR pathway [5,6]. Secondly, it has both pro-apoptotic effects [7-9] and anti-apoptotic effects [10,11] in different cells. Thirdly, it reduces the level of the RNA binding protein HuR in the cytoplasm, decreasing the stability of mRNAs encoding
 20 proliferative genes such as cyclins A and B1 [12]. Fourthly, it inhibits proliferation of HepG2 cells by stabilizing p53 [13].

We have previously partially purified from rat liver an upstream kinase, AMPKK, that activates AMPK by phosphorylation at Thr-172 within the
 25 activation loop of the kinase domain [14]. However, we have been unable to purify enough material to obtain amino acid sequence and identify the activity as a defined gene product. We searched for kinases upstream of the *Saccharomyces cerevisiae* homologue of AMPK (the SNF1 complex), by assaying the ability of a collection of 119 yeast protein kinase-glutathione-

S-transferase (GST) fusions to activate the mammalian and yeast kinases. This approach identified the Elm1 protein kinase as a potential upstream kinase [15]. By analysing protein kinases that interacted with Snf1 by two hybrid analysis, Schmidt and colleagues identified Pak1 as another potential
 5 upstream kinase in yeast [16]. Neither *elm1Δ* nor *pak1Δ* strains, in which the single kinase genes were deleted, had the same phenotype as a *snf1Δ* strain. However, Elm1 and Pak1 form a small sub-family with the Tos3 protein kinase, and a triple *elm1Δ pak1Δ tos3Δ* mutant strain had phenotype similar to *snf1Δ* that was restored to wild type by expression of
 10 any one of the three kinases [15]. This proved that these three protein kinases act as upstream kinases for the SNF1 complex in a partially redundant manner.

The nearest relatives of Elm1, Pak1 and Tos3 encoded by the human
 15 genome are the β isoform of calmodulin-dependent protein kinase kinase (CaMKK β). We have previously shown that a CaMKK purified from pig brain could activate AMPK in cell-free assays, albeit rather poorly in comparison to the activation of calmodulin-dependent protein kinase I (CAMKI). However, the AMPKK previously purified from rat liver was not
 20 calmodulin-dependent [17]. Amongst other less closely related relatives to the Elm1/Pak1/Tos3 family in humans is LKB1 (see alignment in Fig. 1), a 50 kDa serine/threonine kinase that was originally discovered as the gene mutated in the inherited disorder Peutz-Jeghers syndrome (PJS) [18,19], as discussed above. Several human tumour cell lines, including HeLa and
 25 G361 (melanoma) cells, lack expression of LKB1 mRNA and protein, and expression of wild type LKB1 in these cells caused a growth arrest in G1 phase, whereas expression of catalytically inactive or several LKB1 mutations isolated from PJS mutations failed to arrest cell growth [23]. Growth arrest induced by expression of LKB1 in G361 cells was also

reported to be reversed by co-expression of cyclin D1 or E, was associated with the transcriptional induction of the cyclin-dependent kinase inhibitor p21^{WAF1/CIP1}, and was shown to be dependent on p53 [24]. Taken together, these results show that LKB1 acts as a tumour suppressor and that the catalytic activity of LKB1 is essential for this function. However, the downstream substrate(s) that LKB1 phosphorylates to mediate the suppression of cell growth remained unknown.

We identify MO25 α (MOuse protein 25- α) as a novel component of the LKB1-STRAD α complex and establish that MO25 α plays an important role in stabilising this complex in the cell cytoplasm as well as enhancing LKB1 catalytic activity. For each of STRAD α and MO25 α there is also a closely related isoform (STRAD β and MO25 β) encoded in the human genome, which can also associate with LKB1. We demonstrate that MO25 may function as a scaffolding component of the LKB1-STRAD complex. Although STRAD α [30] and STRAD β are related to the Ste20 protein kinases, several of the residues expected in an active protein kinase are not conserved, and they are therefore classified as “pseudokinases”. MO25 α (for example) binds to the C-terminus of, for example, STRAD α and stabilizes the association between STRAD α and LKB1. The association of LKB1 with STRAD and MO25 increases the kinase activity against an artificial substrate (myelin basic protein) and also enhances its cytoplasmic localization, which was previously implicated in the tumour suppressor function of LKB1, since mutants lacking a nuclear localisation signal were still capable of suppressing cell growth [24].

Further, we describe the resolution from rat liver of two upstream kinases (AMPKK1 and AMPKK2). We show that AMPKK1 and AMPKK2 both contain LKB1 complexed with STRAD α and MO25 α , and that both

activities are immunoprecipitated with anti-LKB1 antibodies. Moreover, both endogenous and recombinant LKB1/STRAD/MO25 complexes isolated from HEK-293T cells activate AMPK via phosphorylation of Thr-172 on the α subunit. We demonstrate that the ability of LKB1 to phosphorylate and activate AMPK is enhanced dramatically by the presence of STRAD and MO25 subunits, suggesting that both subunits are essential for maximal activity. Finally, drugs that activate AMPK in other cell types (AICA riboside and phenformin), did not activate the AMPK in HeLa cells, which do not express LKB1. However, the stable expression of wild type LKB1, but not a catalytically-inactive mutant, restored activation of AMPK by these drugs. Accordingly, we show that the LKB1, in complex with STRAD and MO25, is the physiological activator of AMPK. It is now possible to perform screens for identifying compounds for modulating the physiological activation of AMPK.

A first aspect of the invention provides a method for identifying a compound for use in modulating, for example promoting, the activation or phosphorylation of AMPK (AMP-activated protein kinase) or AMPK subfamily member in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example promotes, the protein kinase activity of LKB1 and (2) selecting a compound which modulates, for example promotes, the protein kinase activity of LKB1.

The protein kinase activity of LKB1 that is modulated/assessed in the screening method may be phosphorylation of a non-physiological substrate such as myelin basic protein (for example as discussed in the Examples). Alternatively, the protein kinase activity of LKB1 that is modulated/assessed in the screening method may be phosphorylation of AMPK or an AMPK subfamily member, or fragment either thereof, as

discussed further. Phosphorylation of AMPK or an AMPK subfamily member may be assessed by measuring activation or phosphorylation of the AMPK or AMPK subfamily member, as discussed further below and in the Examples. For example, AMPK activation may be assessed using a
5 reporter gene whose expression is modulated by AMPK.

The protein kinase activity may be increased or reduced by an alteration in the V_{\max} or the K_m (or both) of the LKB1 (or AMKP or subfamily member, as appropriate) for a particular substrate. For example, activity may be
10 increased by an increased V_{\max} or decreased K_m . It will be appreciated that it may not be necessary to determine the value of either V_{\max} or K_m in order to determine whether the LKB1 (or AMKP or subfamily member, as appropriate) has been activated or deactivated. It will be appreciated that dephosphorylated (deactivated) AMPK or subfamily member may retain
15 some enzymatic activity.

Activity may be measured as the amount of a substrate phosphorylated in a given time; a change of activity may therefore be detected as a change in the amount of substrate (for example, at a single concentration) that is
20 phosphorylated in a given time. It is preferred that the activity is increased or decreased, as appropriate, by at least 2, preferably 5, 10, 15, 20, 25, 30 or 50-fold.

It will be appreciated that it may be necessary to determine the effect of the
25 compound on the activity of the substrate (for example AMPK), for example by measuring the activity of the substrate when exposed to the compound (1) after exposure of the substrate to LKB1, (2) before exposure of the substrate to LKB1 and/or (3) without exposure to LKB1.

Expression of a protein encoded by an RNA transcribed from a promoter regulated (directly or indirectly) by a substrate of LKB1 (or production of the RNA itself) may be measured. The protein may be one that is physiologically regulated by a substrate of LKB1, for example AMPK or subfamily member, or may be a "reporter" protein, as well known to those skilled in the art (ie a recombinant construct may be used). A reporter protein may be one whose activity may easily be assayed, for example β -galactosidase, chloramphenicol acetyltransferase or luciferase (see, for example, Tan *et al* (1996)).

10

AMPK activation, for example in the liver, decreases the expression of enzymes of gluconeogenesis (phosphoenolpyruvate carboxylase and glucose-6-phosphatase); see Lochhead *et al* 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. *Diabetes*. 2000 Jun;49(6):896-903; Yamauchi *et al* Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med*. 2002 Nov;8(11):1288-95. Another class of genes that are switched off by AMPK, for example in the liver, are those encoding enzymes of fatty acid biosynthesis (fatty acid synthase and AcetylCoA carboxylase); see Woods *et al* Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. *Mol Cell Biol*. 2000 Sep;20(18):6704-11. AMPK activation also reduces the level of 4 transcription factors: Sterol response element binding protein-1C (Zhou *et al* Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest*. 2001 Oct;108(8):1167-74.); hepatocyte nuclear factor-4alpha (Leclerc *et al* Hepatocyte nuclear factor-4alpha

involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. *Diabetes*. 2001 Jul;**50**(7):1515-21); C/EBPalpha and PPAR-gamma (Habinowski *et al* The effects of AICAR on adipocyte differentiation of 3T3-L1 cells. *Biochem Biophys Res Commun*. 5 2001 Sep 7;**286**(5):852-6). Accordingly, such genes (or recombinant genes incorporating regulatory sequences from these genes) may be used as reporter genes.

By modulation of the protein kinase activity is included inhibition or an 10 increase in the protein kinase activity.

It will be appreciated that in the methods of the invention wherein phosphorylation of a polypeptide may occur that the presence of a suitable phosphate donor may be required, as described for the above aspect of the 15 invention. Suitable phosphate donors will be known to those skilled in the art and include ATP, for example as the magnesium salt (MgATP), as described in the Examples.

The LKB1 is preferably in a preparation with STRAD and/or MO25. As 20 noted above, LKB1 is considered to be present in a complex with these polypeptides in cells and the presence of these polypeptides is considered to enhance LKB1 activity. The LKB1 (and preferably also STRAD and/or MO25) may, for example, be purified from cells in which the LKB1 (and preferably also STRAD and/or MO25) are expressed naturally, but it may 25 be more convenient for at least one of the LKB1, STRAD or MO25 to be recombinant.

The term AMPK will be well known to those skilled in the art, as indicated above. The AMPK (or other substrate, for example myelin basic protein)

used in the assay may be recombinant or non-recombinant. The AMPK may be a bacterially-expressed AMPK α 1 catalytic domain (for example as described in [44]) or a heterotrimeric complex such as those described in [45] and in Example 2. The AMPK may have the amino acid sequence of a naturally occurring AMPK, or may be or comprise a fusion polypeptide (for example as described in [45] or Example 2), or may be a fragment or variant of a naturally occurring AMPK that retains the ability to be phosphorylated or activated by LKB1, for example as described in Example 2. Thus, it is preferred that the AMPK is an AMPK that retains a threonine (or serine) residue at the position equivalent to Threonine172 of full length wild-type human α 1 catalytic domain. It is preferred that the AMPK is not a mutant in which Thr172 is replaced by a residue other than serine, for example is replaced by alanine. A fragment derivable from AMPK (or from an AMPK subfamily member) which encompasses the Thr172 residue and at least part of the T-loop sequence which includes this residue, for example at least the 2, 3, 4, 5, 6 or 7 residues C-terminal and N-terminal of this residue, is a suitable substrate for use in the screening method. An example of such a peptide substrate is described in Example 3.

Examples of Accession GI numbers for catalytic domain of human AMPK alpha 1 subunit include:

>gi|5453964|ref|NP_006242.1| LocusLink info protein kinase, AMP-activated, alpha 1 catalytic subunit; AMPK alpha 1; Protein kinase, AMP-activated, catalytic, alpha-1 [Homo sapiens]

25

gi|20178277|sp|Q13131|AAK1_HUMAN 5'-AMP-activated protein kinase, catalytic alpha-1 chain (AMPK alpha-1 chain)

gi|4115829|dbj|BAA36547.1| LocusLink info AMP-activated protein
kinase alpha-1 [Homo sapiens]

Examples of Accession GI numbers for catalytic domain of human AMPK
alpha 2 subunit include:

>gi|11493357|emb|CAC17574.1| dJ758N20.1 (protein kinase, AMP-
activated, alpha 2 catalytic subunit) [Homo sapiens]

>gi|5453966|ref|NP_006243.1| LocusLink info protein kinase, AMP-
activated, alpha 2 catalytic subunit; protein kinase, AMP-activated [Homo
sapiens]

The term LKB1 will similarly be well known to those skilled in the art. The
LKB1 used in the assay may be recombinant or non-recombinant. The
LKB1 may be bacterially expressed, but it is preferred that it is expressed in
a mammalian system and/or expressed alongside STRAD and/or MO25,
preferably both, for example as described in Examples 1 and 2. The LKB1
may have the amino acid sequence of a naturally occurring LKB1, or may be
a fusion polypeptide (for example as described in the Examples), or may be
a fragment or variant of a naturally occurring LKB1 that retains the ability to
phosphorylate or activate AMPK, for example on Thr172 of AMPK, for
example as described in Example 2. Thus, the LKB1 is an LKB1 that
retains an active kinase domain. A fragment of LKB1 which contains the
intact kinase domain but not other regions of LKB1 may be useful; this
region of LKB1 is sufficient to retain protein kinase activity and to interact
with STRAD. The LKB1 used in the assay is not a kinase-dead mutant
such as is described in the Examples. It is preferred that the LKB1 retains
the ability to interact with STRAD and/or MO25, as discussed further
below.

Accession numbers for LKB1 include the following:

AAC15742 Peutz-Jeghers syndrome protein [Homo sapiens]

gi|3063585|gb|AAC15742.1|[3063585]

5

Q15831 Serine/threonine protein kinase 11 (Serine/threonine-protein kinase LKB1) gi|3024670|sp|Q15831|STKB_HUMAN[3024670]

NP_000446 serine/threonine protein kinase 11 [Homo sapiens]

10 gi|4507271|ref|NP_000446.1|[4507271]

It is particularly preferred, although not essential, that the LKB1 polypeptide has at least 30% of the enzyme activity of full-length human LKB1 with respect to the phosphorylation of full-length human AMPK α 1 on residue Thr172 (preferably in the presence of STRAD and MO25) or a peptide substrate encompassing this region, or phosphorylation of myelin basic protein. It is more preferred if the LKB1 polypeptide has at least 50%, preferably at least 70% and more preferably at least 90% of the enzyme activity of full-length human LKB1 with respect to the phosphorylation of full-length human AMPK α 1 on residue Thr172 (preferably in the presence of STRAD and MO25) or a peptide substrate encompassing this region.

Similarly, the terms STRAD or MO25 will similarly be well known to those skilled in the art. For example, a STRAD polypeptide (STRAD α) is described in Baas *et al* (2003) *EMBO J* 22(12), 3062-3072 and in EMBL/GenBank Accession No AF308302. Human STRAD α and STRAD β (NCBI accession number AAM19143) sequences are shown in Figure 10. MO25 polypeptides are described in Miyamoto *et al* (1993);

Karos & Fisher (1999) and Nozaki *et al* (1996) and, for example, in Accession No NP_057373 (human MO25 α) and Q9H9S4 (human MO25 β). Further examples of MO25 polypeptides are shown in Figure 2 and further Accession Nos are given in the figure legend. The STRAD or MO25 used
5 in the assay may be recombinant or non-recombinant. The STRAD or MO25 may be bacterially expressed, but it is preferred that they are expressed in a mammalian system and/or expressed alongside LKB1, for example as described in Examples 1 and 2. The STRAD or MO25 may have the amino acid sequence of a naturally occurring STRAD or MO25, or
10 may be a fusion polypeptide (for example as described in the Examples), or may be a fragment or variant of a naturally occurring STRAD or MO25 that retains the ability for the STRAD to bind to the MO25 and to LKB1, and for the MO25 to bind to the STRAD or complex of LKB1 and STRAD. At least the C-terminal region of MO25 may be required. In view of the
15 sequence conservation throughout the length of MO25 it is considered that it may be desirable to use full length MO25. It is preferred that the STRAD polypeptide has the C-terminal sequence Trp-Asp/Glu-Phe (which MO25 is considered to recognise) but this is not considered to be essential, because MO25 can bind to STRAD lacking these residues when the STRAD is
20 bound to LKB1 (see Example 1). It is also preferred that the pseudokinase domain of STRAD is present, as this may be required for MO25 binding. For example, it is preferred that the STRAD is not a fragment lacking the residues corresponding to the C-terminal 88 amino acids of full length STRAD α (which has a truncated pseudokinase domain and does not interact
25 with human LKB1 or MO25 α). It may be desirable to use full length STRAD.

The capability of, for example, the said polypeptide with regard to interacting with or binding to, for example, a STRAD polypeptide, may be

measured by any method of detecting/measuring a protein/protein interaction, as discussed further below. Suitable methods include yeast two-hybrid interactions, co-purification, ELISA, co-immunoprecipitation, cross-linking studies, structural studies, fluorescence resonance energy transfer (FRET) methods and surface plasmon resonance methods. Thus, the said MO25 (for example human MO25 α) may be considered capable of binding to or interacting with a STRAD polypeptide (for example human STRAD α) if an interaction may be detected between the said MO25 polypeptide and the said STRAD polypeptide by ELISA, co-immunoprecipitation or surface plasmon resonance methods or by a yeast two-hybrid interaction or copurification method, for example as described in Example 1 or Example 2.

It is preferred that the interaction can be detected using a surface plasmon resonance method, as described in, for example WO 00/56864. One polypeptide may be immobilised on the test surface, for example it can be coupled through amino groups to a SensorChip CM5™, according to the manufacturer's instructions, or a biotinylated polypeptide can be bound to an avidin coated SensorChip SA. The other polypeptide (at concentrations between, for example 0 and between 10 μ M and 1.0 μ M, for example 2 μ M) is then injected over the surface and steady state binding determined in each case. From these measurements a K_d can be determined. It is preferred that the interaction has a K_d of less than 8 μ M, more preferably less than 5 μ M, 2 μ M, 1 μ M, 500nM, 300nM, 200nM or 100nM, for example about 150nM. Alternatively, a K_d can be determined for a polypeptide in competition with the immobilised polypeptide. One polypeptide (for example at a concentration of 0.5 μ M) is mixed with free polypeptide (for example, at concentrations between 0 and 3 μ M) and the mixture injected over the immobilised polypeptides. The steady state binding is determined in each

case, from which the K_d of the interaction can be determined using the Cheng-PreScott relationship. Alternatively, the interaction may be expressed in terms of an observed response or relative observed responses, measured in terms of mass of protein bound to the surface.

5

By "variants" of a polypeptide we include insertions, deletions and substitutions, either conservative or non-conservative. In particular we include variants of the polypeptide where such changes do not substantially alter the protein kinase activity or ability to bind to particular binding partners, as appropriate.

10

By "conservative substitutions" is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr.

15 The three-letter or one letter amino acid code of the IUPAC-IUB Biochemical Nomenclature Commission is used herein, with the exception of the symbol Zaa, defined above. In particular, Xaa represents any amino acid. It is preferred that at least the amino acids corresponding to the consensus sequences defined herein are L-amino acids.

20

It is particularly preferred if the polypeptide variant has an amino acid sequence which has at least 65% identity with the amino acid sequence of the relevant human polypeptide, more preferably at least 70%, 71%, 72%, 73% or 74%, still more preferably at least 75%, yet still more preferably at least 80%, in further preference at least 85%, in still further preference at least 90% and most preferably at least 95% or 97% identity with the amino acid sequence of the relevant human polypeptide.

25

It is still further preferred if a protein kinase variant has an amino acid sequence which has at least 65% identity with the amino acid sequence of the catalytic domain of the human polypeptide, more preferably at least 70%, 71%, 72%, 73% or 74%, still more preferably at least 75%, yet still
5 more preferably at least 80%, in further preference at least 83 or 85%, in still further preference at least 90% and most preferably at least 95% or 97% identity with the relevant human amino acid sequence.

It will be appreciated that the catalytic domain of a protein kinase-related
10 polypeptide may be readily identified by a person skilled in the art, for example using sequence comparisons as described below. Protein kinases show a conserved catalytic core, as reviewed in Johnson *et al* (1996) *Cell*, 85, 149-158 and Taylor & Radzio-Andzelm (1994) *Structure* 2, 345-355. This core folds into a small N-terminal lobe largely comprising anti-parallel
15 β -sheet, and a large C-terminal lobe which is mostly α -helical.

The percent sequence identity between two polypeptides may be determined using suitable computer programs, for example the GAP program of the University of Wisconsin Genetic Computing Group and it will be
20 appreciated that percent identity is calculated in relation to polypeptides whose sequence has been aligned optimally.

The alignment may alternatively be carried out using the Clustal W program (Thompson *et al.*, 1994). The parameters used may be as follows:
25 Fast pairwise alignment parameters: K-tuple(word) size; 1, window size; 5, gap penalty; 3, number of top diagonals; 5. Scoring method: x percent.
Multiple alignment parameters: gap open penalty; 10, gap extension penalty; 0.05.
Scoring matrix: BLOSUM.

It will be appreciated that the MO25 sequences shown in Figure 2 are examples of MO25 variants as defined above.

- 5 The residue equivalent to, for example, Thr 172 of full-length human AMPK α 1 may be identified by alignment of the sequence of the polypeptide with that of full-length human AMPK α 1 in such a way as to maximise the match between the sequences. The alignment may be carried out by visual inspection and/or by the use of suitable computer programs, 10 for example the GAP program of the University of Wisconsin Genetic Computing Group, which will also allow the percent identity of the polypeptides to be calculated. The Align program (Pearson (1994) in: Methods in Molecular Biology, Computer Analysis of Sequence Data, Part II (Griffin, AM and Griffin, HG eds) pp 365-389, Humana Press, Clifton). 15 Thus, residues identified in this manner are also "equivalent residues".

It will be appreciated that in the case of truncated forms of AMPK α 1 or in forms where simple replacements of amino acids have occurred it is facile to identify the "equivalent residue".

20

- It is preferred that the polypeptides used in the screen are mammalian, preferably human (or a species useful in agriculture or as a domesticated or companion animal, for example dog, cat, horse, cow), including naturally occurring allelic variants (including splice variants). The polypeptides used 25 in the screen may comprise a GST portion or may be biotinylated or otherwise tagged, for example with a 6His, HA, myc or other epitope tag, as known to those skilled in the art, or as described in Examples 1 and 2. This may be useful in purifying and/or detecting the polypeptide(s).

The effect of the compound may be determined by comparing the rate or degree of phosphorylation of the substrate polypeptide by the LKB1 in the presence of different concentrations of the compound, for example in the absence and in the presence of the compound, for example at a
5 concentration of about 100 μ M, 30 μ M, 10 μ M, 3 μ M, 1 μ M, 0.1 μ M, 0.01 μ M and/or 0.001 μ M.

The compound may mimic the effect of the interaction of STRAD and/or MO25 with LKB1. A compound that mimics the effect of STRAD and/or
10 MO25 on LKB1 may increase the rate or extent of phosphorylation of the substrate polypeptide (for example AMPK or a subfamily member or a fragment any thereof).

By "mimic the effect of the interaction of STRAD and/or MO25 with
15 LKB1" is meant that the compound has a quantitative or qualitative effect on the LKB1, for example on its protein kinase activity or stability, that is the same as an effect of the STRAD or MO25 on the protein kinase, for example on its protein kinase activity or stability, as discussed in Examples 1 and 2. For example, STRAD and MO25 are considered to increase the
20 rate at which LKB1 phosphorylates, for example, AMPK or myelin basic protein; a mimic of STRAD or MO25 may increase the rate at which LKB1 (in the absence of STRAD and/or MO25) phosphorylates a substrate polypeptide, for example AMPK.

25 The AMPK subfamily is discussed in Example 2 (and see also [41]) and includes the following polypeptides:

MELK (Heyer et al., 1999 Expression of Melk, a new protein kinase, during early mouse development. Dev Dyn, 215, 344-351; Heyer et al., 1997 New

member of the Snf1/AMPK kinase family, Melk, is expressed in the mouse egg and preimplantation embryo. *Mol Reprod Dev*, 47, 148-156.)

5 QIK (Xia et al., 2000 The new serine-threonine kinase, Qik, is a target of the Qin oncogene. *Biochem Biophys Res Commun*, 276, 564-570)

SIK (Coyle et al., 2003 Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK. *Mol Cell Biol*, 23, 92-103; Derry et al., 2003 Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. *Oncogene*, 22, 4212-4220; Derry et al., 2000 Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability. *Mol Cell Biol*, 20, 6114-6126; Feldman et al., 2000 The salt-inducible kinase, SIK, is induced by depolarization in brain. *J Neurochem*, 74, 2227-2238; Horike et al., 2002 Roles of several domains identified in the primary structure of salt-inducible kinase (SIK). *Endocr Res*, 28, 291-294.; Lin et al., 2000 SIK (Salt-inducible kinase): regulation of ACTH-mediated steroidogenic gene expression and nuclear/cytosol redistribution. *Endocr Res*, 26, 995-1002.; Llor et al., 1999 BRK/Sik expression in the gastrointestinal tract and in colon tumors. *Clin Cancer Res*, 5, 1767-1777.; Vasioukhin and Tyner, 1997 A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. *Proc Natl Acad Sci U S A*, 94, 14477-14482.; Wang et al., 1999 Cloning of a novel kinase (SIK) of the SNF1/AMPK family from high salt diet-treated rat adrenal. *FEBS Lett*, 453, 135-139)

Other family members include NuaK1, NuaK2, BrsK1, BrsK2 and QSK, about which little is known. We consider that LKB1 may phosphorylate and activate these other protein kinases in the AMPK sub-family.

Metformin or its analogues may be acting through activation of one of these kinases as well as through AMPK. Such a sub-family member or fragment thereof or fusion of such a fragment (for example a T-loop peptide, as discussed above and in Example 3) may be a suitable substrate for use in the screening method of the first aspect of the invention.

A compound identified by a method of the invention may modulate the ability of the protein kinase to phosphorylate different substrates, for example different naturally occurring members of the AMPK subfamily, to different extents. Thus, it is preferred, but not essential, that when screening for a compound for use in modulating AMPK activity that AMPK or a fragment thereof is used as the substrate. Similarly, it is preferred, but not essential, that when screening for a compound for use in modulating the activity of a particular AMPK subfamily member that that subfamily member or a fragment thereof is used as the substrate.

The method is useful in identifying compounds that, for example, promote the activation of AMPK or a sub-family member. A compound that triggers the activation of AMPK or an AMPK sub-family member may be useful in the treatment of diabetes and obesity. Such a compound may mimic the activity of metformin or its analogues and may be of higher potency.

LKB1 is also a tumour suppressor protein kinase that inhibits cell growth and proliferation. The results presented herein indicate that LKB1's tumour suppressor functions may be mediated through LKB1 phosphorylating and triggering the activation of AMPK and/or one or more subfamily members indicated above. Thus, these polypeptides may be novel tumour suppressor protein kinases and a compound which activates one or more of these protein kinases may be useful for treating cancer.

A compound which promotes phosphorylation or activation of AMPK or an AMPK family member may act by stabilising the LKB1-STRAD-MO25 complex. It may be useful to screen for such a stabilising effect (either
5 before or after or instead of selection on the basis of a protein kinase activity assay as described above). For example, such a screen could involve assessing the effects of a compound on complex formation or stability, for example using methods for assessing molecular interactions, as discussed above. For example, coimmunoprecipitation or copurification
10 methods may be used, or a reporter gene/yeast two hybrid system may be used. A complex may also be detected using fluorescence resonance energy transfer (FRET) techniques (for example using fusion proteins comprising fluorescent proteins, for example green, blue or yellow fluorescent proteins (GFPs; YFPs, BFPs, as well known to those skilled in the art)), for example
15 in material from cells in which the LKB1 and the STRAD and/or MO25 are coexpressed, as described in Examples 1 and 2.

The compound may be one which binds to or near a region of contact between two or more of LKB1, STRAD and MO25, or maybe one which
20 binds to another region and, for example, induces a conformational or allosteric change which stabilises (or destabilises) the complex; or promotes (or inhibits) its formation. The compound may bind to LKB1 or STRAD or MO25 (or to the complex as a whole) so as to increase the LKB1 protein kinase activity by an allosteric effect. This allosteric effect may be an
25 allosteric effect that is involved in the natural regulation of LKB1's activity.

A further aspect of the invention provides a purified preparation comprising LKB1, STRAD and recombinant MO25. The preparation may comprise

recombinant LKB1 and/or recombinant STRAD. The preparation may be useful in an assay of the first aspect of the invention.

By "purified" is meant that the preparation has been at least partially
5 separated from other components in the presence of which it has been
formed, for example other components of a recombinant cell. Examples of
methods of purification than may be used are described in the Examples.

The preparation may be substantially pure. By "substantially pure" we
10 mean that the said polypeptide(s) are substantially free of other proteins.
Thus, we include any composition that includes at least 30% of the protein
content by weight as the said polypeptides, preferably at least 50%, more
preferably at least 70%, still more preferably at least 90% and most
preferably at least 95% of the protein content is the said polypeptides.

15 Thus, the invention also includes compositions comprising the said
polypeptides and a contaminant wherein the contaminant comprises less
than 70% of the composition by weight, preferably less than 50% of the
composition, more preferably less than 30% of the composition, still more
20 preferably less than 10% of the composition and most preferably less than
5% of the composition by weight.

The invention also includes the substantially pure said polypeptides when
combined with other components *ex vivo*, said other components not being
25 all of the components found in the cell in which said polypeptides are
found.

A further aspect of the invention provides a cell capable of expressing
LKB1, STRAD and overexpressed or recombinant MO25. The cell may

comprise a recombinant nucleic acid encoding MO25, and/or a recombinant nucleic acid encoding LKB1, and/or a recombinant nucleic acid encoding STRAD. The cell may be capable of overexpressing MO25 from the endogenous sequence encoding MO25, for example using techniques of sequence-specific targeting of transcription activators. The cell may be a prokaryotic or eukaryotic cell. For example it may be a eukaryotic cell, for example an insect, yeast or mammalian cell, for example a human cell. Examples of suitable cells are described, for example, in the Examples.

The recombinant nucleic acid is preferably suitable for expressing the encoded polypeptide. The recombinant nucleic acid may be in the form of an expression vector. Recombinant polynucleotides suitable for expressing a given polypeptide are well known to those skilled in the art, and examples are described in Examples 1 and 2.

A further aspect of the invention provides a cell comprising LKB1, STRAD and overexpressed or recombinant MO25. The cell may comprise recombinant LKB1 and/or recombinant STRAD. The cell may be a cell according to the preceding aspect of the invention. The cell may comprise at least 1.1, 1.2, 1.5, 2, 3, 5, 10 or 20-fold more MO25 (or LKB1, or STRAD, as appropriate) than an equivalent cell which has not been modified in order to overexpress MO25 or to express recombinant MO25.

By "suitable for expressing" is meant that the polynucleotide is a polynucleotide that may be translated to form the polypeptide, for example RNA, or that the polynucleotide (which is preferably DNA) encoding the polypeptide of the invention is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. The polynucleotide may be linked to the appropriate transcriptional and

translational regulatory control nucleotide sequences recognised by any desired host; such controls may be incorporated in the expression vector.

Characteristics of vectors suitable for replication in mammalian/eukaryotic cells are well known to those skilled in the art, and examples are given below. It will be appreciated that a vector may be suitable for replication in both prokaryotic and eukaryotic cells.

A variety of methods have been developed to operably link polynucleotides, especially DNA, to vectors for example *via* complementary cohesive termini. Suitable methods are described in Sambrook *et al* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

A desirable way to modify the DNA encoding a polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki *et al* (1988) *Science* **239**, 487-491. This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art.

In this method the DNA to be enzymatically amplified is flanked by two specific primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

The DNA (or in the case of retroviral vectors, RNA) is then expressed in a suitable host to produce a polypeptide comprising the compound of the

invention. Thus, the DNA encoding the polypeptide constituting the compound of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter *et al*, 4,530,901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crowl, 4,677,063 issued 30 June 1987 to Mark *et al*, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura *et al*, 4,710,463 issued 1 December 1987 to Murray, 4,757,006 issued 12 July 1988 to Toole, Jr. *et al*, 4,766,075 issued 23 August 1988 to Goeddel *et al* and 4,810,648 issued 7 March 1989 to Stalker, all of which are incorporated herein by reference.

The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA

sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

5

Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then
10 be recovered.

Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells, animal cells and
15 insect cells.

The vectors include a prokaryotic replicon, such as the ColE1 *ori*, for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an
20 appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as *E. coli*, transformed therewith.

A promoter is an expression control element formed by a DNA sequence
25 that permits binding of RNA polymerase and transcription to occur. Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention.

Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and pTrc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.

- 5 A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells.
- 10 An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to drive expression of the cloned gene.
- 15 Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers *HIS3*, *TRP1*, *LEU2* and *URA3*. Plasmids pRS413-416 are Yeast
20 Centromere plasmids (YCps).

The host cell can be either prokaryotic or eukaryotic. Bacterial cells are preferred prokaryotic host cells and typically are a strain of *E. coli* such as, for example, the *E. coli* strains DH5 available from Bethesda Research
25 Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic cell line. Yeast host cells include

YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include human embryonic kidney 293 cells (see Example 1), Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, and monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors.

Transformation of appropriate cell hosts with a DNA construct is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen *et al* (1972) *Proc. Natl. Acad. Sci. USA* **69**, 2110 and Sambrook *et al* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman *et al* (1986) *Methods In Yeast Genetics, A Laboratory Manual*, Cold Spring Harbor, NY. The method of Beggs (1978) *Nature* **275**, 104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA.

Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

For example, many bacterial species may be transformed by the methods described in Luchansky *et al* (1988) *Mol. Microbiol.* **2**, 637-646

incorporated herein by reference. The greatest number of transformants is consistently recovered following electroporation of the DNA-cell mixture suspended in 2.5X PEB using 6250V per cm at 25:FD.

- 5 Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol.* **194**, 182.

Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For
10 example, cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the invention. Cells can be harvested and lysed and their DNA content examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* **98**, 503 or Berent *et al* (1985)
15 *Biotech.* **3**, 208.

In addition to directly assaying for the presence of recombinant DNA, successful transformation can be confirmed by well known immunological methods when the recombinant DNA is capable of directing the expression
20 of the protein. For example, cells successfully transformed with an expression vector produce proteins displaying appropriate antigenicity. Samples of cells suspected of being transformed are harvested and assayed for the protein using suitable antibodies.

- 25 Thus, in addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium.

A further aspect of the invention method for making a preparation of the invention, comprising the step of purifying the preparation from a cell according to the invention. . Methods of cultivating host cells and isolating recombinant proteins are well known in the art. Examples of suitable purification techniques are described in the Examples. For example, one or more component of the preparation may be tagged so as to aid purification using affinity reagents, as will be well known to those skilled in the art and as described in the Examples. Chromatographic techniques may also be used, for example as described in the Examples.

10

A further aspect of the invention provides a preparation obtained or obtainable by the method of the preceding aspect of the invention. The preparation may comprise, for example, tagged LKB1, STRAD or MO25. The ratios of LKB1:STRAD:MO25 may be 1:1:1, for example as measured using techniques as described in the Examples. It will be appreciated that the ratio determined may vary depending upon the details of the method used in providing the preparation. The preparation may comprise a complex comprising the LKB1, STRAD and MO25, as described in the Examples.

20

The method of the first aspect of the invention may be performed with LKB1 in the form of a preparation of the second aspect of the invention; or a preparation or complex obtained or obtainable by the method as indicated above; or in a cell of the invention.

25

The above polypeptides may be made by methods well known in the art and as described below and in Example 1 or 2, for example using molecular biology methods or automated chemical peptide synthesis methods.

It will be appreciated that peptidomimetic compounds may also be useful. Thus, by "polypeptide" or "peptide" we include not only molecules in which amino acid residues are joined by peptide (-CO-NH-) linkages but also molecules in which the peptide bond is reversed. Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Mézière *et al* (1997) *J. Immunol.* 159, 3230-3237, incorporated herein by reference. This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains. Mézière *et al* (1997) show that, at least for MHC class II and T helper cell responses, these pseudopeptides are useful. Retro-inverse peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are much more resistant to proteolysis.

Similarly, the peptide bond may be dispensed with altogether provided that an appropriate linker moiety which retains the spacing between the C α atoms of the amino acid residues is used; it is particularly preferred if the linker moiety has substantially the same charge distribution and substantially the same planarity as a peptide bond.

It will be appreciated that the peptide may conveniently be blocked at its N- or C-terminus so as to help reduce susceptibility to exoproteolytic digestion.

Thus, it will be appreciated that the STRAD or MO25 polypeptide may be a peptidomimetic compound.

A further aspect of the invention provides a method for identifying a compound for modulating cellular LKB1 activity, the method comprising the steps of (1) determining whether a test compound modulates (for example increases) the LKB1 protein kinase activity of a preparation or

complex or cell as defined in relation to any preceding aspect of the invention and (2) selecting a compound which modulates the said LKB1 protein kinase activity. The LKB1 protein kinase activity may be measured using, for example, myelin basic protein as a substrate, or using AMPK or
5 AMPK subfamily member or a fragment thereof (as discussed above and in Example 3) as the substrate. A compound which modulates, for example increases LKB1 protein kinase activity may be useful in medicine, for example for treating cancer.

10 The compounds identified in the methods may themselves be useful as a drug or they may represent lead compounds for the design and synthesis of more efficacious compounds.

The compound may be a drug-like compound or lead compound for the
15 development of a drug-like compound for each of the above methods of identifying a compound. It will be appreciated that the said methods may be useful as screening assays in the development of pharmaceutical compounds or drugs, as well known to those skilled in the art.

20 The term "drug-like compound" is well known to those skilled in the art, and may include the meaning of a compound that has characteristics that may make it suitable for use in medicine, for example as the active ingredient in a medicament. Thus, for example, a drug-like compound may be a molecule that may be synthesised by the techniques of organic
25 chemistry, less preferably by techniques of molecular biology or biochemistry, and is preferably a small molecule, which may be of less than 5000 daltons. A drug-like compound may additionally exhibit features of selective interaction with a particular protein or proteins and be bioavailable

and/or able to penetrate cellular membranes, but it will be appreciated that these features are not essential.

The term "lead compound" is similarly well known to those skilled in the art, and may include the meaning that the compound, whilst not itself suitable for use as a drug (for example because it is only weakly potent against its intended target, non-selective in its action, unstable, difficult to synthesise or has poor bioavailability) may provide a starting-point for the design of other compounds that may have more desirable characteristics.

It will be understood that it will be desirable to identify compounds that may modulate the activity of the protein kinase *in vivo*. Thus it will be understood that reagents and conditions used in the method may be chosen such that the interactions between, for example, the said LKB1 and, for example, the STRAD or MO25 polypeptides, are substantially the same as between the human LKB1 and human STRAD and/or MO25. It will be appreciated that the compound may bind to the LKB1, or may bind to the STRAD or MO25.

The compounds that are tested in the screening methods of the assay or in other assays in which the ability of a compound to modulate the protein kinase activity of a protein kinase, for example LKB1, may be measured, may be compounds that have been selected and/or designed (including modified) using molecular modelling techniques, for example using computer techniques. The selected or designed compound may be synthesised (if not already synthesised) and tested for its effect on the LKB1, for example its effect on the protein kinase activity. The compound may be tested in a screening method of the invention.

It will be appreciated that screening assays which are capable of high throughput operation will be particularly preferred. Examples may include the cell based assays described and protein-protein binding assays. A further example is an SPA-based (Scintillation Proximity Assay; Amersham International) system as well known to those skilled in the art. Other methods of detecting polypeptide/polypeptide interactions include ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Fluorescence Energy Resonance Transfer (FRET) methods, for example, well known to those skilled in the art, may be used, in which binding of two fluorescent labelled entities may be measured by measuring the interaction of the fluorescent labels when in close proximity to each other

A further aspect of the invention is a compound identified or identifiable by a screening method of the invention.

A still further aspect of the invention is a compound of the invention for use in medicine.

The compound may be administered in any suitable way, usually parenterally, for example intravenously, intraperitoneally, subcutaneous or intramuscular or intravesically, in standard sterile, non-pyrogenic formulations of diluents and carriers. The compound may also be administered topically. The compound may also be administered in a localised manner, for example by injection. The treatment may consist of a single dose or a plurality of doses over a period of time. The compound may be useful as an anticancer agent or for the treatment of, for example, diabetes or obesity.

Whilst it is possible for a compound of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation, together with one or more acceptable carriers. The carrier(s) must be "acceptable" in the sense of being compatible with the compound of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

Thus, the invention also provides pharmaceutical compositions comprising the compound identified or identifiable by the screening methods of the invention and a pharmaceutically acceptable carrier.

A further aspect of the invention provides a kit of parts comprising LKB1 or a recombinant polynucleotide encoding LKB1, STRAD or a recombinant polynucleotide encoding STRAD, and MO25 or a recombinant polynucleotide encoding MO25. A further aspect of the invention provides a kit of parts comprising (1) AMPK or AMPK subfamily member, or recombinant polynucleotide encoding AMPK or AMPK subfamily member (including a fragment thereof as discussed above or in Example 3) and (2) a kit of parts as defined in relation to the preceding aspect of the invention, or a preparation or complex or cell of the invention. Such kits may be useful in forming a preparation or complex which may be useful in, for example a screening method of the first aspect of the invention. The recombinant polynucleotide(s) may be in an expression vector (for example as discussed above) or (less desirably) useful for *in vitro* expression.

A further aspect of the invention provides a method for overexpressing LKB1 comprising the steps of (1) selecting a cell type in which to overexpress LKB1, comprising the step of determining whether the cell type is one that expresses STRAD and/or MO25, and (2) overexpressing

LKB1 in the selected cell type. Methods for determining whether the cell type expresses STRAD and/or MO25 will be well known to those skilled in the art, and examples of such methods are described in the Examples. Alternatively, the cell type may be one that is already known to express STRAD and/or MO25. Examples of such cells include 293, HeLa, G361 and Rat2 cells. STRAD α and MO25 α are expressed at good levels in most cells analysed.

A further aspect of the invention provides a method for preparing LKB1 comprising the steps of (1) overexpressing LKB1 in a cell using a method according to the preceding aspect of the invention and (2) preparing LKB1 from the cell. By this is included preparing LKB1 in a preparation or complex with STRAD and MO25. Suitable methods for preparing LKB1 are described in the Examples.

Overexpression of LKB1 may lead to growth arrest, for example in eukaryotic cells. It may therefore be necessary to express LKB1 using a transient expression system, for example as described in the Examples, or using a regulated (inducible) expression system, as well known to those skilled in the art.

A further aspect of the invention provides a method for identifying a putative binding partner for MO25 comprising the steps of (1) providing an amino acid sequence of at least the C-terminal three amino acids of a test putative binding partner (2) selecting a putative binding partner having the C-terminal amino acid sequence Trp-Glu/Asp-Phe. The method may further comprise the step of determining that the selected putative binding partner binds to MO25, for example using methods for assessing molecular

interactions as indicated above. The motif Trp-Glu/Asp-Phe is considered to be involved in the interaction between MO25 and STRAD.

5 A further aspect of the invention provides a method for identifying a genetic difference associated with PJS (Peutz-Jeghers Syndrome) comprising the steps of (1) investigating the sequence of a gene encoding a STRAD or MO25 isoform in at least one patient having PJS (2) identifying any difference between the said patient sequence and equivalent sequence from an individual without PJS. The association of LKB1 with STRAD and
10 MO25 and the association of LKB1 deficiency with PJS suggests that defects in MO25 or STRAD could also be involved in PJS. Techniques for identifying mutations in candidate genes, and for investigating whether a mutation is linked with disease or is not so linked will be well known to those skilled in the art.

15

A further aspect of the invention provides a method for determining whether an individual is susceptible to PJS comprising the steps of determining whether the test individual has a genetic difference identified as associated with PJS by a method according to the preceding aspect of the
20 invention. It may also be useful to determine whether an individual who has PJS has a genetic difference identified as associated with PJS by a method according to the preceding aspect of the invention, in order to determine what treatment may be suitable. For example, a patient who is found to have a defect in STRAD or MO25 may be treated using STRAD or
25 MO25 or a genetic construct which allows STRAD or MO25 to be expressed in cells where it is needed.

Thus, the invention provides STRAD or MO25 or a recombinant polynucleotide encoding same for use in medicine. A further aspect of the

invention provides the use of STRAD or MO25 or a recombinant polynucleotide encoding same in the manufacture of a medicament for treating cancer, PJS, diabetes or obesity. The recombinant polynucleotide may be in the form of a gene therapy vector, for example a viral gene therapy vector, as well known to those skilled in the art.

A further aspect of the invention method for identifying a compound which activates AMPK or AMPK subfamily member by a similar mechanism to metformin or phenformin or AICA riboside in which the effect of a test compound on the activation of AMPK or AMPK subfamily member by a preparation or complex or cell of the invention is compared with the effect of metformin or phenformin or AICA riboside on the activation of AMPK or AMPK subfamily member and a compound with a similar effect is selected. Such a method may be useful in determining whether a compound is more potent than metformin or phenformin or AICA riboside.

A further aspect of the invention provides the use of an AMPK subfamily member (other than AMPK) or polynucleotide encoding an AMPK subfamily member (other than AMPK) in the manufacture of a medicament for treating diabetes or obesity.

Published documents referred to herein are hereby incorporated by reference.

The invention is now described further by reference to the following, non-limiting, Figures and Examples.

Figure Legends

Figure 1. Association of MO25 α with LKB1. (A) Cell lysates derived from control parental HeLa cells or HeLa cells stably expressing N-terminal

Flag epitope tagged wild type (WT) LKB1 or kinase dead (KD) LKB1 were passed through an anti-Flag M2-affinity agarose column, LKB1 eluted with the Flag peptide and the samples concentrated as described in Materials and Methods. The samples were electrophoresed on a polyacrylamide gel and the protein bands visualised following colloidal blue staining. Protein bands unique to the WT and KD LKB1 preparations are indicated. (B) The colloidal blue-stained bands labelled as indicated in (A) were excised from the gel, the proteins digested in gel with trypsin, and their identities were determined by tryptic peptide mass-spectral fingerprint. The identity of STRAD α and MO25 α were confirmed by LC-MS/MS sequence analysis on a Q-TOF2 mass spectrometer. The number of tryptic peptides, percentage of sequence coverage and NCBI gi numbers for each protein identified are indicated. (C) The samples purified in (A) were immunoblotted with the indicated antibodies. Identical results were obtained following 2 independent purifications of LKB1 from HeLa cells.

Figure 2. Amino acid sequence and tissue distribution patterns of MO25 α and MO25 β isoforms. (A) Amino acid sequence alignment of the human MO25 α (NCBI accession number NP_057373) and MO25 β (NCBI accession number Q9H9S4) isoforms as well as *C. elegans* MO25 α (NCBI accession number CAB16486) and MO25 β (NCBI accession number NP_508691) and *Drosophila* MO25 (NCBI accession number P91891) putative homologues. Conserved residues are boxed in black, and homologous residues are shaded in grey. Sequence alignments were performed using the CLUSTALW and BOXSHADE programmes at <http://www.ch.embnet.org/> using standard parameters. (B) A ^{32}P -labelled fragment of the MO25 α cDNA was used to probe a Northern blot

containing polyadenylated RNA isolated from the indicated human tissues. The membrane was autoradiographed, and the MO25 α probe was observed to hybridise to a 4.2-kb message, identical to the size predicted for the MO25 α message from database analysis. As a loading control, the Northern
5 Blot was hybridised with a β -actin probe. (C & D) The indicated mouse tissue (C) or cell (D) extracts containing 20 μ g of total cell protein were immunoblotted with the anti-MO25 α and anti-MO25 β antibodies.

Figure 3. Endogenous LKB1 is associated with MO25 α . (A) LKB1 was
10 immunoprecipitated from 2 mg of the indicated lysates using 10 μ g of anti-LKB1 antibody covalently coupled to protein G-Sepharose, and the immunoprecipitates were immunoblotted with the indicated antibodies. As a control, immunoprecipitations were also performed in parallel experiments with preimmune IgG antibodies covalently coupled to protein G-Sepharose.
15 In each gel, 20 μ g of total cell lysate was also immunoblotted in parallel. (B) MO25 α was immunoprecipitated as above except that 15 μ g of the MO25 α antibody was employed. The results shown are from a single experiment that was repeated 3 times with similar results.

Figure 4. MO25 α is associated with LKB1 through STRAD (A) 293
20 cells were transfected with plasmids encoding for the expression of the indicated GST fusion proteins together with Myc-MO25 α . 36 h post transfection, the GST tagged proteins were affinity purified from the cell lysates using glutathione-Sepharose as described in Materials and Methods.
25 Similar amounts of the purified GST-fusion proteins were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted with anti-Myc antibody to detect co-purified Myc-MO25 α , or with anti-GST antibody to

ensure that comparable amounts of the GST tagged proteins were present in each lane (upper and middle panels). 5 µg of total cell lysates prior to affinity purification were also subjected to immunoblotting with anti-Myc antibody to ensure that Myc-MO25α was expressed at similar levels in each co-transfection (lower panel). (B) N-terminal GST tagged LKB1 was expressed in 293 cells in the presence or absence of Flag-STRADα and purified as above. The purified proteins were subjected to SDS-polyacrylamide gel electrophoresis and visualised by Colloidal blue staining (upper panel). The faint protein band indicated, corresponding to an endogenous protein of 40-kDa (marked *), was identified by tryptic peptide mass-spectral fingerprint as endogenously expressed MO25α (with 38% sequence coverage). The purified proteins were also immunoblotted with the indicated antibodies (lower panels). (C) As above except that GST-LKB1 was expressed in 293 cells together with the indicated isoforms of Flag-STRAD and Myc-MO25 and the proteins visualised by colloidal blue staining were also immunoblotted with the indicated antibodies. For all panels, similar results were obtained in at least 3 separate experiments.

Figure 5. MO25α and STRADα anchor LKB1 in the cytoplasm. HeLa cells were transfected with the indicated constructs encoding for the expression of Myc-MO25α, Flag-STRADα and GFP-LKB1. 24 h post transfections the cells were fixed in 4% (by vol) paraformaldehyde and immunostained with anti-MO25α antibody to detect MO25α (TR anti-sheep secondary antibody, red channel) and anti-Flag to detect STRADα (Cy5 anti-mouse secondary antibody, blue channel). GFP-LKB1 localisation was visualised directly through the GFP fluorescence (green channel). The cells were imaged using a Zeiss LSM 510 META confocal

microscope. The cells shown are representative images obtained in 3 separate experiments. The scale bars correspond to 10 μm .

Figure 6. MO25 α recognises the C-terminal 3 residues of STRAD α . (A) N-terminal GST tagged wild type STRAD α or the indicated mutants of STRAD α were expressed in 293 cells together with Myc-MO25 α , and 36 h post transfection the STRAD α proteins were affinity purified from the cell lysates using glutathione-Sepharose. Similar amounts of the purified proteins were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotting with anti-Myc antibody to detect co-purified Myc-MO25 α , or with anti-GST antibody to ensure that comparable amounts of the GST tagged proteins were present in each lane (upper and middle panels). 5 μg of the total cell lysates prior to affinity purification were also subjected to immunoblotting with anti-Myc antibody to ensure that Myc-MO25 α was expressed at similar levels in each condition (lower panel). (B) 0.5 mg of the indicated cell lysates was incubated with 5 μg of an N-terminal biotinylated peptide encompassing either the C-terminal 12 residues STRAD α conjugated to streptavidin-Sepharose (NLEELEVDWDF, termed STRAD α -C12) or mutants of this peptide in which the indicated residues were individually mutated to Ala. Following isolation and washing of the beads, the samples were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotted with an anti-MO25 α antibody. (C) Binding of bacterially expressed MO25 α to the indicated peptides was analysed by surface plasmon resonance Biacore analysis as described in Materials and Methods. Binding was analysed over a range of MO25 α concentrations (6.25-3200 nM) and the response level at the steady-state binding was plotted versus the log of the MO25 α concentration. The

estimated K_d for the STRAD α -C12 peptide was obtained by fitting the data to the formula $[m1 \times m0 / (m0 + m2)]$ using Kaleidagraph software and the K_d was calculated to be 850 nM. WEF-C12 corresponds to NLEELEVDDWEF, WEA-C12 corresponds to NLEELEVDDWEA, AEF-C12 corresponds to NLEELEVDDAEF, WAF-C12 corresponds to NLEELEVDDWAF, WEF-C6 corresponds to VDDWEF.

Figure 7. Binding of LKB1 to STRAD α creates novel binding site(s) for MO25 α . The indicated forms of GST-STRAD α were co-expressed in 293 cells together with Myc-MO25 α and/or wild type Flag-LKB1 or the isolated LKB1 catalytic domain (LKB1[44-343]. 36 h post-transfection, the GST-STRAD α proteins were affinity purified, subjected to SDS-polyacrylamide gel electrophoresis and immunoblotting with anti-Myc antibody to detect Myc-MO25 α , anti-Flag antibody to detect co-purified Flag-LKB1 and Flag-LKB1[44-343], or with anti-GST antibody to detect STRAD α forms (upper panels). 5 μ g of total cell lysates prior to affinity purification were also subjected to immunoblotting with anti-Myc and anti-Flag antibodies to ensure that MO25 α and LKB1 were expressed at similar levels in each co-transfection (lower panels). Similar results were obtained in 3 separate experiments.

Figure 8. MO25 isoforms stabilise the LKB1-STRAD α complex. (A) 293 cells were transfected with 3 μ g of the DNA construct encoding for expression of GST-LKB1, in the presence or absence of 3 μ g of Flag-STRAD α construct and in the absence or presence of indicated amounts of Myc-MO25 α construct. 36 h post-transfection, GST-LKB1 was affinity purified from the cell lysates and immunoblotted with appropriate epitope

antibodies to detect LKB1, STRAD α and MO25 α . 5 μ g of total cell lysates prior to affinity purification were also immunoblotted with the indicated antibodies (lower panels). (B) is performed as above except that the MO25 β construct was employed instead of the MO25 α construct. Similar results were obtained in 3 separate experiments.

Figure 9. Activation of LKB1 by association with STRAD and MO25 isoforms. 293 cells were transfected with constructs encoding GST-LKB1 in the presence or absence of constructs encoding the indicated isoforms of STRAD and MO25. 36 h post-transfection, GST-LKB1 was affinity purified and assayed for autophosphorylation and transphosphorylation of MBP as described in the materials and methods. The reactions were electrophoresed and the gel autoradiographed (top panel). Phosphorylation of MBP by LKB1 at Thr65 was also monitored by immunoblotting with a phosphospecific antibody (T65-P), which recognises MBP phosphorylated by LKB1 at this residue. Each reaction was also immunoblotted with the appropriate epitope tag antibodies to monitor levels of LKB1, STRAD and MO25 isoforms. Similar results were obtained in 3 separate experiments.

Figure 10. Amino acid sequence alignment of STRAD isoforms with closest STE20-kinase relatives. (A) Amino acid sequence alignment of the human STRAD α (NCBI accession number AAG48269) and STRAD β (NCBI accession number AAM19143) with human SPAK (NCBI accession number AAC72238) and human OSR1 (NCBI accession number NP_005100). Conserved residues are boxed in black, and homologous residues are shaded in grey. The catalytic Asp (subdomain VI) and Asp-Phe-Gly (subdomain VII) present in the active SPAK and OSR1 protein

kinases, but lacking in the STRAD α and STRAD β pseudokinases are boxed and marked with an asterisk. The C-terminal Trp-Glu-Phe motif present in STRAD α and STRAD β corresponding to a Phe-Glu-Phe sequence in SPAK and OSR1 are boxed and marked with triangles and the sites of LKB1 phosphorylation in STRAD α (Thr329 and Thr419) (Baas et al., 2003) are marked with arrows. Sequence alignments were performed using the CLUSTALW and BOXSHADE programmes at <http://www.ch.embnet.org/> using standard parameters.

Figure 11. MO25 isoforms increase expression of STRAD β and formation of the LKB1-STRAD β complex. (A) 293 cells were transfected with 3 μ g of the DNA construct encoding for expression of GST-LKB1, in the presence or absence of 3 μ g of Flag-STRAD β construct and in the absence or presence of indicated amounts of Myc-MO25 α construct. 36 h post-transfection, GST-LKB1 was affinity purified from the cell lysates and immunoblotted with appropriate epitope antibodies to detect LKB1, STRAD β and MO25 α . 5 μ g of total cell lysates prior to affinity purification were also immunoblotted with the indicated antibodies (lower panels). (B) is performed as above except that the MO25 β construct was employed instead of the MO25 α construct. Similar results were obtained in 3 separate experiments and also when STRAD β was expressed as a GST-fusion protein in the pEBG-2T vector instead of the pCMV5 vector (data not shown).

Figure 12: Alignment of the amino acid sequences of Tos3, Pak1 and Elm1 from yeast and LKB1 and CaMKK β (β 3 variant) from humans. The alignment was created using PILEUP from the GCH suite [49] and the consensus sequence determined and colouring added using BOXSHADE

v3.2.1 [50]. Residues that are identical in at least half of the sequences are coloured grey, with conservative changes also in grey. The consensus sequence is represented by an upper case letter if the residue at a particular position is identical in all sequences, and by a lower case letter if at least half are conserved. Only the conserved central regions containing the kinase domains (residues 50-310 of LKB1 approx.) are shown.

Figure 13: Two AMPKKs can be resolved from rat liver extracts but both are complexes between LKB1, STRAD α and MO25 α . (A) Separation of two activities that activate GST-AMPK α 1-catalytic domain by Q-Sepharose chromatography. The graph shows AMPKK activity in fractions (open circles, absorbance at 280 nm (continuous line) and conductivity in the eluate (dashed line). The "x" axis represents the fraction number (4.5 ml fractions). B, C, D: probing of blots of column fractions after SDS-PAGE (1 μ l per lane) using anti-LKB1 (B), anti-STRAD α (C) and anti-MO25 α (D). E, F, G: Fractions 26-30 were concentrated from 4.5 ml to 250 μ l using Amicon Ultra-4 30,000 MWCO centrifugal concentrators, and 2 μ l was loaded per lane. Following SDS-PAGE the gels were transferred to nitrocellulose and the membranes probed with anti-LKB1 (E), anti-STRAD α (F) and anti-MO25 α (G).

Figure 14: AMPKK activity, and the LKB1, STRAD α and MO25 α polypeptides, can be immunoprecipitated from rat liver AMPKK1 and AMPKK2 using anti-LKB1 antibody. (A) Depletion of AMPKK activity from supernatant. Sheep anti-human LKB1 or pre-immune control immunoglobulin (IgG) was pre-bound to Protein G-Sepharose beads and crosslinked with DMP as described previously [51], except that a final wash of the beads with 100 mM glycine, pH2.5, was performed. Bead-bound antibodies (40 μ l) were incubated with the peak fraction of AMPKK1 (0.04

Units), AMPKK2 (0.03 Units) or recombinant GST-LKB1:STRAD α :MO25 α complex (0.06 Units) for 20 minutes and the beads removed in a microcentrifuge (14,000 \times g, 2 min). AMPKK activity was determined in the supernatants and is expressed as a percentage of the value obtained using the control IgG. (B) The pellets from the experiment in (A) were resuspended in the original volume and samples of the supernatants and pellets analysed by Western blotting with anti-LKB1 antibody. The recombinant LKB1 migrates at a higher molecular mass because of the GST tag. (C) As A, except that the amount of AMPKK1, AMPKK2 and recombinant GST-LKB1-STRAD α -MO25 α complex were increased to 0.44, 0.70 and 1.4 Units respectively, and the activities were determined in the resuspended pellets. In this experiment the amount of antibody was limiting so only a portion of the activity was precipitated. (D) The pellets from the experiment in (C) were resuspended and samples analysed by Western blotting with anti-LKB1, anti-STRAD α and anti-MO25 α antibodies.

Figure 15: Recombinant LKB1-STRAD-MO25 complexes can efficiently activate AMPK via phosphorylation at Thr-172. (1): the indicated combinations of GST-tagged wild type LKB1 (WT, lanes 1-9), or kinase-dead (D194A, KD, lanes 10-13) LKB1 mutant, or GST-alone (lane 14), FLAG-tagged STRAD α or STRAD β , and *myc*-tagged MO25 α or MO25 β were co-expressed in HEK-293T cells, purified on glutathione-Sepharose and tested for their ability to activate GST-AMK α 1 catalytic domain (top panel). Samples from each incubation were also analysed by Western blotting and probed using the indicated antibodies (from top to bottom: anti-pT172, anti-AMPK α 1 catalytic domain (GST- α 1), anti-GST to detect GST-LKB1, anti-FLAG to detect STRAD α and STRAD β , and anti-*myc* to detect MO25 α and MO25 β . All proteins migrated with the

expected mobility, taking into account the epitope tags. The bottom three blots were conducted on blank reactions lacking GST-AMPK α 1 catalytic domain, as the latter appeared to cause some interference with detection. (B): recombinant GST-LKB1:STRAD α :MO25 α complex was used to phosphorylate wild type GST- α 1 catalytic domain (GST- α 1-WT) or a T172A mutant (GST- α 1-T172A) using [γ -³²]ATP as described under Methods. The reaction was analysed by SDS-PAGE and autoradiography. Arrows show the migration of GST-LKB1 (which autophosphorylates) and GST- α 1 catalytic domain.

10

Figure 16: Activation and phosphorylation of heterotrimeric AMPK complexes by AMPKK1, AMPKK2 and recombinant GST-LKB1:STRAD α :MO25 α complexes. recombinant α 1 β 1 γ 1 or α 2 β 1 γ 1 complexes were incubated for 10 min with MgATP and AMPKK1 (2.8 or 1.4 units/ml), AMPKK2 (10.3 or 5.15 units/ml) or GST-LKB1:STRAD α :MO25 α (14.3 or 7.2 units/ml), and AMPK activity determined. Twice as much upstream kinase was added when the α 1 β 1 γ 1 complex was the substrate, as pilot experiments showed that it was activated less readily. The images are of Western blots probed with phosphospecific anti-pT172 antibody (upper panel), and with a mixture of anti- α 1 and - α 2 antibodies to demonstrate uniform loading of the α 1 β 1 γ 1 or α 2 β 1 γ 1 complexes (note that the anti- α 2 antibody always gives a stronger signal than anti- α 1 even for equal protein loadings).

20

Figure 17: Endogenous AMPKK activity can be immunoprecipitated from 293 cells using anti-LKB1 antibody, but activity can only be immunoprecipitated from HeLa cells if they stably express LKB1 (but not a catalytically-inactive mutant) from an inducible promoter. LKB1 was immunoprecipitated from 0.5 mg of cell extract derived from untransfected

25

HEK-293T cells (lanes 1,2), untransfected HeLa cells (lanes 3,4), or HeLa cells stably expressing wild type (WT) LKB1 (lanes 5,6) or a kinase-dead (KD) LKB1 (D194A) mutant (lanes 7,8) from an inducible promoter. Immunoprecipitation was with anti-LKB1 (lanes 1,3,5,7) or a pre-immune control immunoglobulin (IgG, lanes 2, 4, 6, 8). Samples of each immunoprecipitate were used to assay activation of GST-AMPK α 1-catalytic domain, to analyze phosphorylation of GST-AMPK α 1-catalytic domain on Thr-172 (middle panel), and to determine recovery of LKB1 (bottom panel). Samples of each immunoprecipitate were also immunoblotted for the presence of endogenous STRAD α and MO25 α with appropriate antibodies. Also shown in the top panel is the basal activity obtained when the GST-AMPK α 1-catalytic domain was incubated with MgATP on its own (no addition).

Figure 18: Restoration of the ability of AMPK to be activated by AICA riboside and phenformin in HeLa cells by expression of LKB1. Control HeLa cells (lanes 1, 2,3), HeLa cells expressing wild type (WT) LKB1 (lanes 4,5,6) and kinase dead (D194A, KD) mutant LKB1 (lanes 7, 8, 9) were either left unstimulated or treated with 2 mM AICA riboside or 10 mM phenformin for 60 min and lysed. (A) Endogenous AMPK was immunoprecipitated from the cell extracts and assayed. (B) The cell lysates was immunoblotted with antibodies recognising AMPK α 1 phosphorylated at Thr172 or total AMPK α 1; the results were analysed using the LI-COR IR OdysseyTM imager as described under Materials and Methods, and are expressed as a ratio of the two signals. (C) The cell lysates was analysed by Western blotting and the membranes probed with antibodies recognising ACC phosphorylated at Ser-79, or streptavidin to determine total AMPK α 1. The results were analysed using the LI-COR IR imager as for (B).

Figure 19: Sequence alignment of the activation loop sequences of AGC sub-family kinases (PKA α and PKC α , which are not thought to be activated by LKB1) with the T-loop residues of the AMPK/ SNF1 subfamily of protein kinases. The methods and representation are as described in Figure 1. The threonine residues corresponding to Thr-172 of AMPK ("P") and other residues mentioned in the text are indicated with downward arrows. All sequences are from humans, except AtSnRK1- α 1, AtSnRK1- α 2 and ScSnf1, which are the *Arabidopsis thaliana* (AtSnRK1, SNF1-related kinase-1) and *Saccharomyces cerevisiae* (ScSnf1) homologues of AMPK. Although the human, *Arabidopsis* and *S. cerevisiae* homologues, as well as the PKA α and PKC α kinases, are known to be activated by phosphorylation of the threonine residue equivalent to Thr-172, it has yet to be established whether the other AMPK subfamily members (NuaK1, NuaK2, BrsK1, BrsK2, SIK, QIK, QSK, MELK) are activated by phosphorylation of this residue, and whether LKB1-STRAD-MO25 complexes can mediate this phosphorylation.

Figure 20: Km and Vmax for a peptide substrate (termed AMPKtide). Assay conditions are described in Example 3.

Example 1: MO25 isoforms interact with the STE20-related pseudokinases STRAD α / β and enhance their ability to bind, activate and localise the LKB1 tumour suppressor in the cytoplasm

Mutations in the LKB1 protein kinase result in the inherited Peutz Jeghers Cancer Syndrome. Research to date has indicated that LKB1 functions as a tumour suppressor protein but still little is known about how LKB1 is regulated. Recent work revealed that LKB1 can be activated through its interaction with the STE20-related, catalytically inactive pseudokinase

termed STRAD α and that this interaction was required for LKB1 to suppress cell growth. In this Example we have found that the endogenous LKB1-STRAD α complex immunoprecipitated from a number of mammalian cells is also associated with a 40-kDa protein of unknown function, containing no identifiable functional domains, termed MO25 α . We show that MO25 α does not bind directly to LKB1 but instead is associated with LKB1 through its interaction with STRAD α . MO25 α specifically recognises the last 3 residues of STRAD α (Trp-Glu-Phe) as mutation or truncation of these amino acids abolishes the interaction of STRAD α with MO25 α . Cellular localisation studies indicate that MO25 α and STRAD α form a cytoplasmic complex anchoring LKB1 in the cytoplasm, excluding it from the nucleus. The amount of LKB1 associated with STRAD α in cells is markedly increased by overexpression of MO25 α , suggesting that MO25 α enhances the formation of the LKB1-STRAD α complex in vivo. We also establish that the association of LKB1 with STRAD α and MO25 α stimulates the catalytic activity of LKB1 nearly 10-fold. Moreover, we provide evidence that the closely related isoform of STRAD α (also known as ILPIP or PAP kinase), which we named STRAD β , and MO25 β isoforms are also able to stabilise LKB1 in an active complex, and we demonstrate that it is possible to isolate heterotrimeric complexes of LKB1 bound to STRAD and MO25 isoforms, in which the subunits are present in equimolar amounts. Our results indicate that the MO25 may function as a scaffolding component of the LKB1-STRAD complex and play a crucial role in regulating LKB1 activity and cellular localisation mediated by its interaction with the STRAD pseudokinases.

Results

Identification of MO25 α in an LKB1 complex.

In order to identify proteins associated with LKB1, we have utilised previously described HeLa cells stably expressing low levels of either the wild type or catalytically inactive LKB1 with an N-terminal Flag epitope tag to enable facile immuno-purification of LKB1-associated proteins employing the Flag antibody (Boudeau et al., 2003a). Flag-LKB1 was immuno-purified from one hundred 10 cm dishes of HeLa cell lysate derived from the cells expressing wild type LKB1 or kinase dead LKB1, or from the control parental HeLa cell line that does not express LKB1 (see Materials and Methods). The preparations were subjected to electrophoresis on a polyacrylamide gel, which was stained with colloidal blue (Fig 1A). A sample of the kinase dead LKB1 preparation was also concentrated further to enable better visualisation of lower abundance proteins. Several bands were observed which were present in both the wild type and kinase dead LKB1 preparations, but were absent in the control sample (Fig 1A). The identity of the colloidal blue-stained bands labelled in Figure 1A was established by tryptic peptide mass-spectral fingerprinting procedures (Fig 1B), and confirmed by immunoblotting with appropriate antibodies (Fig 1C). Proteins previously established to be associated with LKB1, including the Hsp90 and Cdc37 chaperone proteins (Boudeau et al., 2003a) and STRAD α (Baas et al., 2003) were detected. In addition, a protein of ~40 kDa identified as MO25 α , co-immuno-purified with both wild type and kinase dead LKB1 but was not present in the control purification (Fig 1A and 1C).

MO25 α was first identified as a gene expressed at the early cleavage stage of mouse embryogenesis (Miyamoto et al., 1993) and was shown to be a highly evolutionary conserved protein (Karos and Fischer, 1999; Nozaki et

al., 1996) for which no cellular function has been ascribed. From analysis of databases, we have identified a closely related isoform of MO25 α , which we termed MO25 β , and a sequence alignment of both MO25 isoforms together with their putative homologues in *Drosophila* and *C. elegans* is shown in Figure 2A. Northern blot analysis indicated that MO25 α is widely expressed in human tissues, with highest levels of expression in skeletal muscle (Fig 2B). Immunoblot analysis using an antibody raised against the MO25 α protein, which does not cross react with MO25 β (Fig 2C & D), and analysis of EST databases (Table 1) confirmed that MO25 α is expressed in many tissues and cell lines. Although we were unable to detect significant levels of MO25 β RNA by Northern blot analysis, immunoblotting using an antibody raised against the MO25 β protein, which does not cross react with MO25 α , suggested that MO25 β is also expressed in a variety of tissues and cell lines tested (Fig 2D). This is consistent with the observation that MO25 β EST sequences have been identified from a number of human tissues (Table 1). However, expression of MO25 β may be more restricted than MO25 α , as it was not detected in liver and several cell lines including HeLa cells (Fig 2D), perhaps explaining why it was not co-purified with LKB1 expressed in these cells (Fig 1).

Supplementary table. Tissue origin of ESTs encoding human MO25 α and MO25 β

<i>Protein</i>		<i>Tissue NCBI Accession</i>	
5	MO25 α	duodenum, adenocarcinoma	NM_016289
		leiomyosarcoma	BM474393, BU167673, BE884976
		embryonal carcinoma	BQ433499, BM905560, BG259357
		squamous cell carcinoma	BG679680
		melanotic melanoma	BQ432236
10		mammary adenocarcinoma	BM013638, BG034567
		chronic lymphotic leukemia	AI760873
		ductal carcinoma	BU190932
		osteosarcoma	BG108474
15		adenocarcinoma	BG250662, BG121835, AW188515
		metastatic chondrosarcoma	CA436298
		epithelioid carcinoma	BQ433038
		retinoblastoma	BM480142
		neuroblastoma	BE383169
20		uterus, tumor	BF095794
		melanotic melanoma	BE891921, BQ231688
		astrocytoma	BM913690, BM560554
		transitional cell papilloma	G260085
		skin tumor	AA379224
25		testis	BG773506, BG719459
		sympathetic trunk	BQ718408
		marrow	BI019682, BI019684
		normal pigmented retinal epithelium	BG750933, BM050770
		cervix	BI089979
30		hypothalamus	AV722015, AV729226
		fetal brain	BM927264, AA351866
		senescent fibroblasts	W47588
		infant brain	AA434013,, R21390, R46486
		germinal center B cell	AA280522, AA280264, AA262054
35		ovarian tumor	AA442950, AA165271, AA164403
		placenta	R67490, R66347, BG435220,
		osteosarcoma	BG025988
		breast, normal	BE004664, AW373436
		fetal liver spleen	T86658, T86848
40		cervix	BE538532
		stomach	BM822360, BM833391, BM766941
		fetal eyes	BM711209
		purified pancreatic islet	BU079122, BU078843
		prostate, normal	BE835801
45		lung	BM979124, BM982100, BM985320
		kidney	AW235071, AA961656

	MO25 β	prostate	BF680686
		placenta, choriocarcinoma	BC010993, BE281207, BF107447
		teratocarcinoma	AU125107, AU148840, AK022639
5		parathyroid, tumor	W37952
		sciatic nerve	BQ899617
		germinal center B cell	AA278473, AA279145
		lung tumor	BF879769
10		epidermoid carcinoma	BQ669953
		lung, normal	BF845952, BE042886,
		colon	BE928225, AW008806
		metastatic chondrosarcoma	BQ021348
		fibrosarcoma	CA441154
		kidney	AW242839
15		stomach	BM820071, BM831835, BM822014
		liver and spleen	AI247543
		testis	AA781806
		pancreas	AI956166
20		retina	AA001436, AA018841

Endogenous MO25 α is present in complex with endogenous LKB1. We next immunoprecipitated endogenous LKB1 from 293 cells (Fig 3A, left panel) or Rat-2 cells (Fig 3A, right panel), followed by immunoblotting for LKB1, STRAD α and MO25 α . The experiments showed that MO25 α , as well as STRAD α , were co-immunoprecipitated with LKB1, but not with preimmune IgG. We also immunoprecipitated endogenous MO25 α from 293 cells (Fig 3B, left panel) or Rat-2 cells (Fig 3B, right panel), and immunoblotted for the presence of LKB1, STRAD α and MO25 α (Fig 3B). Endogenous LKB1 and STRAD α were co-immunoprecipitated with MO25 α , but not with preimmune IgG, consistent with the notion that these proteins form a complex.

MO25 interacts with STRAD rather than with LKB1.

To verify which component of the LKB1-STRAD complex MO25 α interacted with, we co-transfected 293 cells with constructs expressing MO25 α and either N-terminal glutathione S-transferase (GST) tagged LKB1, STRAD α or the closely related STRAD β pseudokinase, as well as
5 Cdc37, a chaperone previously shown to bind LKB1 (Boudeau et al., 2003a). A sequence alignment of STRAD α and STRAD β is shown in the Figure 10 and both lack the same key conserved residues in subdomain VI and VII in the kinase domain that are required for catalysis. The GST-tagged proteins were affinity purified and immunoblotted for MO25 α (Fig
10 4A). We found that MO25 α interacts only with STRAD α and STRAD β but not with LKB1 or Cdc37.

We next expressed LKB1 in 293 cells in the presence or absence of STRAD α , and the protein composition of the affinity purified LKB1 was
15 analysed following electrophoresis and staining with colloidal blue. As expected, STRAD α was co-purified with LKB1. However, in addition, a faintly staining band corresponding to an endogenous protein of ~40 kDa was observed in the LKB1-STRAD α complex, which was not present in the uncomplexed LKB1 preparation. Tryptic peptide mass spectral
20 fingerprinting revealed that this protein corresponded to endogenous MO25 α . This was confirmed by immunoblotting with an anti-MO25 α antibody (Fig 4B), further suggesting that MO25 α is associated with LKB1 through STRAD α . In Figure 4C, we demonstrate by performing appropriate co-transfections, that it is possible to purify a heterotrimeric LKB1 complex
25 in which LKB1, STRAD α and MO25 α are present in equivalent equimolar proportions. We also demonstrate that it is possible to form similar complexes of LKB1-STRAD α -MO25 β , LKB1-STRAD β -MO25 α and

LKB1-STRAD β -MO25 β (Fig 4C), indicating that both isoforms of STRAD and MO25 are able to bind each other, as well as LKB1.

MO25 α cooperates with STRAD α to localise LKB1 in the cytoplasm.

5 The cytoplasmic fraction of LKB1 was recently shown to conduct a G1 cell arrest (Tiainen et al., 2002). Therefore, we were interested in studying how the formation of a complex of LKB1, STRAD α and MO25 α affected the localisation of these proteins. HeLa cells were transfected with combinations of tagged MO25 α , STRAD α and LKB1 and these proteins
10 were visualised in cells by confocal fluorescence microscopy in which the MO25 α , STRAD α and LKB1 proteins could be detected independently in the same cell. MO25 α (Fig 5A) and STRAD α (Fig 5E) expressed on their own were localised throughout the cytoplasm and nucleus. Strikingly however, when MO25 α and STRAD α were co-expressed, both proteins
15 were re-localised to the cytoplasm and were excluded from the nucleus (Fig 5G & 5H). As reported previously in COS cells, LKB1 expressed alone was mainly nuclear (Fig 5L) and co-expression with STRAD α promoted significant cytoplasmic localisation of LKB1, however significant levels of LKB1 remained in the nucleus under these conditions (Fig 5O) (Baas et al.,
20 2003). In the presence of both MO25 α and STRAD α however, LKB1 was essentially only localised in the cytoplasm and virtually excluded from the nucleus (Fig 5R). These observations indicate that MO25 α and STRAD α form a complex that anchors LKB1 in the cytoplasm more effectively than STRAD α alone.

25 *MO25 α recognises the last 3 residues of STRAD α .*

To define the binding site of MO25 α on STRAD α , a series of deletion mutations of STRAD α were tested for their ability to interact with MO25 α in a co-transfection binding assay. Strikingly, deletion of only the last 3 amino acids of STRAD α (Trp-Glu-Phe) abolished binding of MO25 α to STRAD α . Moreover, mutation of the C-terminal Trp residue to Phe, also vastly reduced binding of MO25 α to STRAD α (Fig 6A). We then tested whether it was possible to affinity purify endogenously expressed MO25 α from 3 different mammalian cell lysates employing biotinylated peptides encompassing the C-terminal residues of STRAD α conjugated to streptavidin-Sepharose. We found that a peptide encompassing the C-terminal 12 residues (Fig 6B) but not the last 6 residues (data not shown and Fig 6C) of STRAD α efficiently purified endogenous MO25 α from all cell lysates tested (Fig 6B). To further delineate the MO25 α binding site on the STRAD α peptide, we performed an alanine scan, mutating each residue of the peptide individually to Ala and verifying how this affected binding to MO25 α (Fig 6B). Consistent with the Trp-Glu-Phe residues being required for MO25 α recognition, mutation of any of these 3 residues in the C-terminal STRAD α peptide abolished or vastly reduced MO25 α binding in 3 different cell lysates, whereas mutation of the other residues either did not affect binding or only had a moderate effect. These findings were also confirmed in a more quantitative surface plasmon resonance Biacore binding assay (Fig 6C).

Binding of LKB1 to STRAD α creates novel binding site(s) for MO25 α .

We next investigated how binding of LKB1 to STRAD α affected the interaction with MO25 α using a co-expression binding assay in 293 cells in which full length wild type and deletion mutants of GST-STRAD α were co-

expressed in the presence or absence of MO25 α and LKB1. Consistent with previous findings, STRAD α mutants that lack either the C-terminal 12 or 48 residues did not bind MO25 α in the absence of LKB1 (Fig 7, panel 1). Strikingly though, when these STRAD α mutants were co-expressed with LKB1, MO25 α was recovered in the purified complexes (Fig 7, panel 2), indicating that the binding of LKB1 to STRAD α generates additional binding site(s) for MO25 α within the LKB1-STRAD α complex. We also consistently noticed that the amount of LKB1 recovered in the GST-STRAD α pull downs was significantly higher in the presence of MO25 α (Fig 7, compare panels 2 and 3), suggesting that MO25 α might stabilise the formation of a heterotrimeric LKB1 complex. Moreover, a catalytic fragment of LKB1 encompassing only the kinase domain (residues 44-343) interacted much more efficiently with STRAD α in the presence of MO25 α (Fig 7, compare panels 4 and 5). These observations indicate that MO25 α could be stabilising the LKB1-STRAD α complex by generating additional MO25 α binding site(s) on STRAD α and/or LKB1. However, a mutant of STRAD α lacking the C-terminal 88 residues that truncates a region of the pseudokinase domain, was no longer able to interact with LKB1 or MO25 α when these proteins were co-expressed (Fig 7). This suggested that either a secondary MO25 α binding site is located towards the C-terminus of STRAD α or that the integrity of the pseudokinase domain, which could be disrupted by truncation of the 88 C-terminal residues of STRAD α , is required in enabling formation of the LKB1-STRAD α -MO25 α heterotrimeric complex.

Further evidence that MO25 stabilises the LKB1-STRAD complex.

To obtain further evidence that MO25 α could stabilise the binding of LKB1 to STRAD α , 293 cells were co-transfected with constructs expressing LKB1 and STRAD α in the absence or presence of increasing amounts of the MO25 α DNA construct. LKB1 was purified and the levels of associated STRAD α and MO25 α were measured by immunoblotting. As a control, the levels of expression of LKB1, STRAD α and MO25 α were also measured in the cell lysates prior to affinity purification of LKB1. In the absence of MO25 α , a moderate amount of STRAD α was associated with LKB1, which was markedly enhanced by increasing expression of MO25 α in a dose dependent manner (Fig 8A, upper panel). Increased association of STRAD α with LKB1 was not due to increased expression of LKB1 or STRAD α as these were expressed in cell lysates at similar levels in the absence or presence of increasing amounts of MO25 α (Fig 8A, lower panel). MO25 β was similarly able to enhance the interaction between LKB1 and STRAD α (Figure 8B).

We also investigated how MO25 α and MO25 β stabilised the binding of LKB1 to STRAD β (Fig 11). No detectable association of STRAD β was observed to LKB1 in the absence of MO25, whereas co-expression of MO25 α or MO25 β resulted in a dose dependent increase in STRAD β binding to LKB1. However, in contrast to STRAD α , the levels of STRAD β expression in 293 cells were low in the absence of MO25 isoforms and significantly increased in their presence, which could explain the increased binding of LKB1 to STRAD β in the presence of MO25 isoforms (Supplementary Fig 2). Similar results were obtained when STRAD β was expressed as a GST-fusion protein from a distinct expression vector (data not shown).

Stabilisation of the LKB1-STRAD complex by MO25 isoforms correlates with increased activity.

To determine how the binding of MO25 α and MO25 β to the LKB1-STRAD α or LKB1-STRAD β complex affected LKB1 activity, 293 cells
 5 were transfected with wild type GST-LKB1 in the presence or absence of STRAD and/or MO25 isoforms. The activity of equal amounts of affinity purified GST-LKB1 was evaluated by measuring autophosphorylation activity as well as the transphosphorylation of myelin basic protein (MBP), a non-specific exogenous substrate of LKB1, in the presence of [γ - 32 P]ATP.
 10 We also monitored MBP phosphorylation using a phospho-specific antibody that recognises the major LKB1 phosphorylation site on MBP (Thr65) (Baas et al., 2003). The different LKB1 activity assays gave comparable results (Fig 9). In the absence of STRAD isoforms, LKB1 was poorly active (Fig 9, lane 1) and, as shown previously (Baas et al., 2003),
 15 co-expression with STRAD α induced an ~4-fold increase in LKB1 activity (Fig 9, lane 2). In the presence of STRAD α and either MO25 α or MO25 β , LKB1 activity was increased a further ~2-fold so that LKB1 became ~9-fold more active than LKB1 expressed alone (Fig 9, lanes 6 or 7). LKB1 was only activated by STRAD β in the presence of MO25 isoforms (Fig 9,
 20 compare lanes 3 with lanes 8 & 9), consistent with the observation that LKB1 is barely associated with STRAD β in the absence of MO25 (Fig 11). LKB1 was previously shown to phosphorylate STRAD α (Baas et al., 2003), and we show that the MO25-mediated increase in the association of STRAD α to LKB1 results in increased STRAD α phosphorylation (Fig 9,
 25 compare lanes 2 with 6 & 7). In contrast to STRAD α , STRAD β was not significantly phosphorylated by LKB1 in the presence of MO25 (Fig 9, lanes 8 & 9). LKB1 phosphorylates STRAD α at Thr329 and Thr419 (Baas

et al., 2003), sites that are not conserved in STRAD β (Fig 10). This explains why STRAD β is not phosphorylated by LKB1. We also showed that catalytically inactive LKB1 is able to associate with both STRAD isoforms in the presence of either isoform of MO25. However, as expected, it is
 5 unable to autophosphorylate or phosphorylate STRAD α or MBP (Fig 9, lanes 10-13).

Discussion.

One of the major findings of this study is the discovery that the highly
 10 conserved MO25 α protein found in many eukaryotic species, for which no function had been ascribed to previously, is present in a complex with STRAD α and LKB1 in vivo. Interestingly, in the absence of LKB1, MO25 α specifically recognises the last 3 amino acids of STRAD α that lie in a Trp-Glu-Phe sequence, and mutation of any of these 3 residues to Ala
 15 essentially prevented the binding of MO25 α to STRAD α . In this regard, MO25 α functions similarly to a PDZ domain, which also recognises the extreme C-terminal residues of its protein binding partners (Songyang et al., 1997). However, there is no homology between a PDZ domain and MO25 α and, to our knowledge, other domains characterised thus far do not possess
 20 this property. The C-terminal non-pseudokinase domain ~50 residues of STRAD α and STRAD β are poorly conserved but, significantly, both terminate with the Trp-Glu-Phe sequence (Fig 10), emphasising that STRAD α and STRAD β have probably evolved to interact specifically with MO25 isoforms. The most closely related proteins to STRAD α and
 25 STRAD β are the active STE20 member kinases termed SPAK (Johnston et al., 2000) and OSR1 (Tamari et al., 1999), which possess all residues

required for protein kinase catalysis (Fig 10) and are therefore active enzymes. Although neither SPAK nor OSR1 terminate in a Trp-Glu-Phe sequence, both possess a Phe-Glu-Phe sequence at a similar region of their C-terminal non-catalytic domain (Fig 10). This observation prompted us to
5 mutate the C-terminus Trp-Glu-Phe sequence of STRAD α to Phe-Glu-Phe and we found that this prevented MO25 α from binding to STRAD α (Fig 6A). This further emphasizes that the presence of a Trp residue three residues from the end of the protein is essential for binding of STRAD α to MO25 α , suggesting that MO25 α will not interact with SPAK or OSR1.

10

Our data indicate that one of the key roles of MO25 α is to stabilise the interaction between LKB1 and STRAD α . This is based on the observation that the amount of STRAD α associated with LKB1 in cells is significantly enhanced by the expression of MO25 α (Fig 8). The finding that STRAD α
15 lacking the C-terminal Trp-Glu-Phe residues can form a complex with MO25 α in the presence of LKB1 (Fig 7) indicates that the interaction of LKB1 with STRAD α generates novel binding site(s) for MO25 α , which could explain how MO25 α stabilises the association of LKB1 with STRAD α . Our findings do not enable us to discriminate whether the
20 additional MO25 α binding site(s) are located within STRAD α and/or LKB1. Detailed structural studies of this complex will be required to address this issue. Our observations are consistent with the notion that MO25 α or MO25 β may function as a scaffolding component of the LKB1-STRAD complex.

25

It has previously been shown that co-expression of STRAD α with LKB1 enhanced LKB1 in vitro activity (Baas et al., 2003) and here we showed

that the association of LKB1-STRAD with MO25 isoforms further enhanced LKB1 activity 2-fold (Fig 9). These results indicate that stabilisation of the LKB1-STRAD α complex by MO25 is accompanied by activation of LKB1. Importantly, however, it should be noted that the
5 complex of LKB1 and STRAD α purified from mammalian 293 cells overexpressing tagged LKB1 and STRAD α is also associated with significant levels of endogenous MO25 α (Fig 4B). It is therefore not possible to measure the activity of the LKB1-STRAD α complex in the absence of MO25 α by expression of these proteins in mammalian cells.
10 Thus we cannot quantify how association of STRAD α with LKB1 in the complete absence of MO25 α affects LKB1 activity. To overcome the problem of association of overexpressed STRAD α with endogenous MO25 α in mammalian cells, we have attempted to combine *E.coli* expressed LKB1, STRAD α and MO25 α to see whether we could form a
15 complex in which LKB1 could be activated. However, this approach was unsuccessful (JB data not shown), which indicate that the association of LKB1 with STRAD α and MO25 α is a complicated process that may require additional factors and/or that this complex may need to be assembled in vivo. We were able to isolate from mammalian cells a
20 heterotrimeric complex in which LKB1, STRAD and MO25 subunits are present at a similar stoichiometry (Fig 4C), suggesting a relatively high affinity of the individual subunits for each other.

We also demonstrated that MO25 α and STRAD α , when expressed alone in
25 cells, are both localised in the cytoplasm and nucleus, but they are only localised in the cytoplasm and excluded from the nucleus when expressed together (Fig 5). The molecular mechanism underlying this observation has

not been investigated. It is possible that the interaction of MO25 α and STRAD α leads to the masking of a nuclear localisation signal, exposure of a novel nuclear export signal or cytoplasmic anchoring motif, or that the STRAD α -MO25 α complex is too large to freely translocate into the nucleus.

5 Under the conditions we have performed our localisation studies in HeLa cells, we found that MO25 α significantly cooperates with STRAD α to localise LKB1 in the cytoplasm of cells, excluding it from the nucleus, as the nuclear exclusion and cytoplasmic localisation of LKB1 observed following expression of LKB1 and STRAD α was markedly enhanced in the
10 presence of MO25 α (Fig 5). Previous studies in COS cells also showed that STRAD α could localise LKB1 in cytoplasm of cells (Baas et al., 2003). However, as our data indicate that significant levels of endogenous MO25 α will bind to the LKB1-STRAD α complex (Fig 4B), it is not possible to rule out that endogenous MO25 isoforms could contribute to cytoplasmic
15 localisation of LKB1 when it is co-transfected with STRAD α . Cytoplasmic localisation of LKB1 may be important, as mutants of LKB1 that can not enter the nucleus still suppress cell growth (Tiainen et al., 2002). Additional mechanisms may also exist to maintain LKB1 in the cell cytoplasm. The interaction of LKB1 with the LIP1 protein has been shown to induce LKB1
20 cytoplasmic localisation (Smith et al., 2001). It has yet to be tested whether LIP1 can interact with the heterotrimeric LKB1-STRAD-MO25 complex, but LIP1 has not been reported to influence LKB1 activity. LKB1 is also prenylated at its C-terminus (Collins et al., 2000; Sapkota et al., 2001), which could promote interactions with cell membranes. Recent work has
25 indicated that prenylation of the *Drosophila* LKB1 homologue is important for association of LKB1 with membranes in controlling cell polarity (Martin and St Johnston, 2003).

Putative MO25 homologues are found not only in mammals, *Drosophila* and *C.elegans* but also found in fission yeast (NCBI accession number NP_594685, 51% identity to human MO25 α), budding yeast (HYM1, 5 NCBI accession number P32464, 33% identity to human MO25 α) and plant (NCBI accession number Q9M0M4, 43% identity to human MO25 α). To our knowledge only the putative budding yeast MO25 homologue termed HYM1, has been investigated and apparently plays a key role in regulating polarized cell growth and cell separation (Bidlemaier et al., 2001; Dorland 10 et al., 2000; Jorgensen et al., 2002). To our knowledge, LKB1 and STRAD homologues have not been reported in yeast and thus it is not clear whether there could be a link between LKB1 regulating polarity in *C. elegans* and *Drosophila* (Martin and St Johnston, 2003; Watts et al., 2000) and HYM1 regulating cell polarity in yeast.

15

It is also possible that MO25 could have functions that are independent of its ability to regulate LKB1. MO25 could interact with other proteins terminating in a similar motif to STRAD α /STRAD β and there are over 20 human proteins that terminate in a Trp-Glu/Asp-Phe motif. It may be 20 interesting to investigate whether any of these bind MO25 isoforms. It is also probable that STRAD α and STRAD β have functions other than regulating LKB1. In this regard, recent work has shown that overexpression of STRAD β in 293 cells protected them against apoptosis by enhancing the ability of the JNK pathway to be activated by overexpression of XIAP, an 25 upstream component of the JNK pathway (Sanna et al., 2002). Moreover, in another study, overexpression of STRAD β was reported to lead to activation of JNK and p38 γ MAP kinases (Nishigaki et al., 2003). The

mechanism by which STRAD β enhanced JNK/p38 γ activation was not defined in these studies and it would be of interest to test whether LKB1 and/or MO25 is involved in these processes.

- 5 A significant number of inherited forms of PJS found in certain families do not exhibit mutations in the LKB1 genes (Buchet-Poyau et al., 2002), indicating that there is a second causative locus for PJS. Genetic analysis to date has excluded LIP1 and provided no evidence that other proteins reported to interact with LKB1 are mutated in these patients (Buchet-Poyau
10 et al., 2002; Resta et al., 2002). The results in this study indicate that it would be worthwhile to verify whether mutations in the genes encoding STRAD or MO25 isoforms occur in any of the PJS families that do not have mutations in the LKB1 gene.
- 15 In conclusion, we define MO25 as a novel component of the LKB1 complex in vivo. Our results indicate that isoforms of MO25 function to stabilise the interaction of LKB1 with the catalytically inactive STRAD pseudokinase isoforms. This markedly enhances LKB1 activity and its cytoplasmic localisation. In future studies to further define the physiological
20 functions of the MO25 and STRAD homologues in regulating LKB1 function, it would also be important to generate mice lacking these genes. The ability to express more active forms of LKB1 heterotrimeric complexes also opens up the opportunity to employ biochemical approaches to search for novel LKB1 substrates.

25

Materials. Protease-inhibitor cocktail tablets were obtained from Roche. Dimethyl pimelimidate and the anti-Flag M2-agarose affinity gel were purchased from Sigma. Tetracyclin-free foetal bovine sera (FBS) was from

Perbio, and other tissue culture reagents were from Biowhittaker unless otherwise stated. Precast SDS/4–12% and 10% polyacrylamide Bis-Tris gels and myelin basic protein (MBP) were obtained from Invitrogen. Sensor chips SA were from BiaCore AB (Stevenage, UK). [γ - 32 P]ATP, 5 Glutathione-Sepharose, Protein G-Sepharose, and Streptavidin-Sepharose High Performance were purchased from Amersham Biosciences.

Peptides. The biotinylated peptides STRAD α -C12 (Biotin-C6spacer-NLEELEVVDDWEF), and STRAD α -C6 (Biotin-C6spacer-VDDWEF) whose sequences encompass the last 12, and 6 residues of STRAD α 10 respectively, the Flag peptide (DYKDDDDK), and peptides used to raise antibodies were synthesised by Dr G. Bloomberg (University of Bristol, UK). The biotinylated peptides encompassing the last 12 residues of STRAD α in which each residue was individually replaced by an Alanine were synthesized using previously described methodology (Lizcano et al., 15 2002).

Antibodies. The LKB1 antibody used for immunoblotting was raised against the mouse LKB1 protein as described previously (Sapkota et al., 2001). As this antibody does not immunoprecipitate efficiently the human LKB1 protein, we raised an antibody in sheep against the human LKB1 20 protein expressed as a GST-fusion protein in *E. coli*, that efficiently immunoprecipitated human and rat LKB1. This antibody was used for all the immunoprecipitating experiments in this study. The anti-MO25 α and anti-MO25 β antibodies were raised in sheep against the MO25 α and MO25 β human proteins expressed in *E. coli* as described below. The LKB1 25 and MO25 antibodies were affinity-purified on CH-Sepharose covalently coupled to the protein antigen used to raise the antibody. The monoclonal antibody recognising the STRAD α protein has been described previously

(Baas et al., 2003). The phospho-specific antibody recognizing MBP phosphorylated at Thr65 (T65-P) was raised in sheep against peptide GHHAARTTHYGSLPQ corresponding to residues 58-72 of bovine MBP in which the underlined residue is phosphothreonine. The antibody was affinity-purified on CH-Sepharose covalently coupled to the phosphorylated peptide and then passed through a column of CH-Sepharose coupled to the non-phosphorylated peptide. Antibody that did not bind to the latter column was selected. Monoclonal antibodies recognizing the GST and Flag epitope tags were obtained from Sigma, the monoclonal antibody recognizing the Myc epitope tag was purchased from Roche, and secondary antibodies coupled to horseradish peroxidase used for immunoblotting were obtained from Pierce. Preimmune IgG used in control immunoprecipitation experiments was obtained from preimmune serum employing Protein G-Sepharose.

General methods and buffers. Restriction enzyme digests, DNA ligations, and other recombinant DNA procedures were performed using standard protocols. DNA constructs used for transfection were purified from *E. coli* DH5 α using Qiagen plasmid Mega kit according to the manufacturer's protocol. All DNA constructs were verified by DNA sequencing, which was performed by The Sequencing Service, School of Life Sciences, University of Dundee, Scotland, UK, using DYEnamic ET terminator chemistry (Amersham Biosciences) on Applied Biosystems automated DNA sequencers. Lysis Buffer contained 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% (w/v) Triton-X 100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol and 'complete' proteinase inhibitor cocktail (one tablet/50 ml). Buffer A contained 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA,

and 0.1% (v/v) 2-mercaptoethanol. SDS sample Buffer contained 50 mM Tris/HCl pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 0.005% (w/v) bromophenol blue, and 1% (v/v) 2-mercaptoethanol.

DNA constructs. Constructs expressing the full length wild type and kinase dead mouse LKB1 have been described previously (Sapkota et al., 2002a; Sapkota et al., 2002b; Sapkota et al., 2001). In order to generate the N-terminal Myc-tagged MO25 α cDNA, a PCR was performed with primers:

5'-

ggatccgccaccatggagcagaagctgatctctgaagaggacttgccgttcccgttgggaagtctcacaaa

t-3' and

5'-ggatccttaagcttcttgctgagctggtctcttc-3' using an IMAGE Consortium EST clone (IMAGE clone 4822388, NCBI Acc. BG719459) as a template. The resulting PCR product was ligated into pCR2.1-TOPO vector (Invitrogen), and subcloned as a *Bam*H1- *Bam*H1 fragment into the pEBG-2T (Sanchez et al., 1994), pCMV5 (Anderson et al., 1989) and pGEX-6T (Amersham) vectors. To generate the N-terminal Myc-tagged MO25 β cDNA, a PCR was performed with primers

5'-

caccggatccgccaccatggagcagaagctgatctctgaagaggacttgccctttagtagaaatcacacaa

aaatcc-3' and 5'- ggatcctcaaggggccgtttcttcaagtctcgg-3' using an IMAGE Consortium EST clone (IMAGE 1958217, NCBI Acc. AI252223) as a template. The resulting PCR product was ligated into pENTR/D-TOPO Gateway intermediate vector (Invitrogen), and converted into Gateway modified pEBG-2T, pCMV5 and pGEX-6T expression vectors. It should be noted that the human MO25 β IMAGE clone we obtained encodes for an Ala instead of a Val at position 153, compared to the submitted sequence (NCBI accession number Q9H9S4). Sequence analysis of the nucleotide

sequence of several independent MO25 β sequences listed in the supplementary Table, indicated that all of these possess an Ala at position 153. Expression constructs for Flag-tagged STRAD α were PCR amplified with primers 5'-

5 ggatccgccaccatggactacaaggacgacgatgacaagtcatttcttgaagtaaaccagagcgaatc-3' and 5'- ggatcctcagaactcccaatcgccacctccagct-3 using a human STRAD α cDNA as a template (Baas et al., 2003). The PCR product was ligated into pCR2.1-TOPO vector and subcloned as a *Bam*H1-*Not*I fragment into pEBG-2T or as a *Bam*H1-*Xba*I insert into pCMV5.

10

In order to clone STRAD β , two IMAGE EST clones (5301936 and 5501540), which together encompass the entire coding sequence were used as templates to generate full length flag-tagged STRAD β cDNA by PCR using primers 5'-

15 ggatccgccaccatggactacaaggacgacgatgacaagtcctcttttggattgcttctgcacttcaag-3' and

5'-ggatccctagaattcccagtatgagtctttttcatc-3'. The PCR product was ligated into pCR2.1-TOPO vector and subcloned as a *Bam*H1-*Bam*H1 fragment into the pEBG-2T and pCMV5 vectors. The catalytic fragment of mouse LKB1 (residues 44-343) possessing an N-terminal Flag epitope tag was PCR amplified from a mouse LKB1 cDNA (Sapkota et al., 2001) using the primers: 5'-

actagtgccaccatggactacaaggacgacgatgacaagaagctcatcggcaagtacctgatgggg-3' and 5'-actagttcagtcctccaggtagggcactacagtcac-3' and subcloned into pCMV5 vector as an *Spe*I-*Spe*I fragment. The construct encoding for the expression of GFP tagged human LKB1 with no other epitope tag was described previously (Boudeau et al., 2003b). Site directed mutagenesis was

25

performed employing standard procedures using the Quickchange mutagenesis kit (Stratagene). Deletion mutations were generated by introducing STOP codons at the indicated positions.

5 **Cell culture conditions and cell lysis.** The generation of HeLa cells stably expressing wild type or kinase dead LKB1 has been described previously (Sapkota et al., 2002b). The cells were cultured in Minimum Essential Medium Eagle supplemented with 10% (v/v) tetracyclin-free FBS, in the presence of 1 X non-essential amino acid solution, 1 X
10 Penicillin/Streptomycin solution (Invitrogen), 100 µg/ml zeocin and 5 µg/ml blasticidin (Invitrogen). Human embryonic kidney (HEK) 293, embryonic fibroblast Rat-2 cells, and HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) FBS. For all experiments, cells were cultured on a 10-cm diameter dish and lysed
15 in 0.5 to 1 ml of ice-cold Lysis Buffer. Lysates were clarified by centrifugation at 4° C for 10 min at 14 000 g.

Immunoblotting. The amounts of proteins indicated in the figure legends were subjected to SDS-polyacrylamide gel electrophoresis and transferred
20 to nitrocellulose. The membranes were blocked for 1 hour in 50 mM Tris/HCl (pH 7.5), 0.15 M NaCl, 0.5% (v/v) Tween containing 10% (w/v) skimmed milk powder for 1 h. The membranes were then incubated in the same buffer containing 1 µg/ml antibody (LKB1, MO25α and MO25β antibodies) or 0.1 µg/ml (STRADα antibody) for 8 h at 4 °C.
25 Immunoblotting with antibody T65-P was carried out as described above, except that the non-phosphorylated peptide corresponding to the antigen used to raise the antibody was included at a concentration of 10 µg/ml.

Immunoblotting with the GST, Flag, and Myc antibodies was carried out as above with 0.5 µg/ml antibody except that skimmed milk powder was replaced with 5% (w/v) BSA. Detection was performed using the appropriate horseradish peroxidase-conjugated secondary antibodies and the enhanced chemiluminescence reagent (Amersham Pharmacia Biotech).

Immunoprecipitation of endogenous LKB1 and MO25α. The LKB1 and MO25α antibodies were covalently coupled to protein G-Sepharose in a ratio of 1 mg of antibody to 1 ml of resin using a dimethyl pimelimidate cross-linking procedure (Harlow and Lane, 1988). Clarified lysates of 293 and Rat-2 cells generated as described above except that 2-mercaptoethanol was omitted from the lysis buffer, containing 2 mg of total cell protein were incubated at 4°C for 1 h on a vibrating platform with 10 µl of the LKB1-protein G-Sepharose conjugate or 15 µl of the MO25α -protein G-Sepharose conjugate. The immunoprecipitates were washed twice with 1 ml of Lysis Buffer (not containing 2-mercaptoethanol) containing 150 mM NaCl and twice with 1 ml of Buffer A (not containing 2-mercaptoethanol). The beads were then resuspended in a volume of 20 µl of Buffer A to which 5 µl of SDS sample buffer lacking 2-mercaptoethanol was added. The samples were subjected to electrophoresis and then immunoblotted for LKB1, STRADα and MO25α as described above.

Expression of GST-fusion proteins in 293 cells and affinity purification.

10-cm diameter dishes of 293 cells were transiently transfected with 3 to 10 µg of the pEBG-2T constructs using a modified calcium phosphate method (Alessi et al., 1996). 36 h post-transfection, the cells were lysed and the clarified lysates were incubated for 1 h on a rotating platform with

glutathione-Sepharose (25 μ l/dish of lysate) previously equilibrated in lysis Buffer. The beads were washed 4 times with lysis Buffer containing 150 mM NaCl and twice with Buffer A. For immunoblotting analysis, the beads were then resuspended in SDS sample Buffer after this step to give a final
5 volume of slurry of 75 μ l, and the samples immunoblotted as described above. For protein kinase assays and gel electrophoresis, the beads were washed a further twice with Buffer A containing 0.27 M sucrose and the proteins were eluted from the resin by incubation with the same buffer containing 20 mM of glutathione. The beads were then removed by
10 filtration through a 0.44- μ m filter and the eluate divided into aliquots and stored at - 80° C.

Expression and purification of GST-MO25 isoforms in *E. coli*. The pGEX-6T constructs encoding N-terminally GST tagged MO25 α or GST
15 tagged MO25 β were transformed into *E. coli* BL21 cells and a 0.5-liter culture was grown at 37°C in Luria-Bertani broth until the absorbance at 600 nm was ~0.7. Isopropyl- β -D-thiogalactopyranoside was then added at a concentration of 250 μ M to induce protein expression, and the cells were cultured for a further 16 h at 26°C. The cells were harvested by
20 centrifugation for 30 min at 5 000 g and resuspended in 25 ml of Lysis Buffer. Lysis was completed by one round of freeze/thawing and ten 15-sec cycles of sonication. The lysate was centrifuged at 4°C for 30 min at 20 000 g, the supernatant filtered through a 0.44 μ m filter and incubated for 1 h on a rotating platform with 1 ml of glutathione-Sepharose previously
25 equilibrated in lysis Buffer. The beads were washed 4 times with lysis Buffer containing 150 mM NaCl, twice with Buffer A and twice with Buffer A containing 0.27 M sucrose. In order to elute MO25 isoforms from

the resin, 15 μ g of GST tagged PreScission protease was added which cleaves the N-terminal GST tag on the GST-fusion proteins. The resin was incubated with the protease for 16 h at 4 °C on a rotating platform and the eluted MO25 proteins collected by filtration through a 0.44- μ m filter. The
5 eluted MO25 isoforms were further incubated with 0.25 ml of glutathione-Sephadex for 30 min at 4°C to remove any traces of uncleaved GST-fusion protein and GST-PreScission protease. 1 mg of homogenous MO25 was typically isolated and after snap freezing in liquid nitrogen stored in aliquots at -80°C.

10 **Purification of Flag-LKB1 and mass spectrometry analysis.** Flag-LKB1 was immuno-purified from HeLa cells stably expressing wild type LKB1 or kinase dead LKB1, or from control HeLa cells using anti-Flag M2-affinity agarose gel as described previously (Boudeau et al., 2003a). For each purification, hundred 10 cm diameter dishes of each HeLa cell line was
15 employed and yielded a 0.4 ml of eluted affinity purified LKB1 solution. 40 μ l of each sample (Fig 1A lane 1-3) were electrophoresed on a precast 4-12% SDS-polyacrylamide gel, and the gel stained with colloidal blue and photographed. For the concentrated sample (Fig 1A, lane 4), 250 μ l of the KD-LKB1 preparation was methanol precipitated, resuspended in 1X SDS
20 Sample Buffer and analysed. The bands indicated in Figure 1A were excised, washed and digested with trypsin as described previously (Woods et al., 2001). Tryptic peptides were analysed by MALDI-TOF mass spectrometry, using α -cyanocinnamic acid as the matrix, on a PerSeptive Biosystems Elite STR mass spectrometer. Spectra were acquired in the
25 reflectron mode, internally calibrated and the tryptic peptide masses were scanned against NCBItr and SwissProt databases using the MS-FIT program of Protein Prospector (UCSF, CA) run on a local server. The

identity of STRAD α and MO25 α was also confirmed by LC-MS/MS sequence analysis on a Q-TOF2 mass spectrometer as described previously (Way et al., 2002).

Affinity purification of MO25 α with peptides. Streptavidin-Sepharose previously equilibrated in PBS was incubated with each biotinylated peptide in a ratio of 1 μ g of peptide to 1 μ l of resin on a vibrating platform for 30 min, and the beads were then washed twice with PBS to remove any unconjugated peptide. The indicated cell lysates (0.5 mg) were incubated with Streptavidin-Sepharose peptide conjugate (5 μ l) for 1 h at 4°C on a vibrating platform. The beads were washed twice with 1 ml of Lysis Buffer containing 150 mM NaCl and twice with 1 ml of Buffer A, and then resuspended in a volume of 20 μ l of Buffer A to which 5 μ l of SDS sample buffer was added. The samples were then subjected to electrophoresis and immunoblotted for MO25 α as described above.

Biacore analysis. Binding was analysed in a Biacore 3000 system (Biacore AB, Stevenage, UK). The indicated biotinylated peptides were bound to a streptavidin-coated Sensor chip (SA) (20 response units, RU). Various concentrations of bacterially-expressed MO25 α previously dialysed in buffer HBS-EP (10 mM HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) polysorbate-20), were injected over the immobilised peptides at a flow rate of 30 μ l/min. Interactions between each peptide and the MO25 α protein were analysed over a range of MO25 α concentrations of 6.25-3200 nM and steady state binding was determined at each concentration. Dissociation of MO25 α from each peptide was monitored over a 1 min period. Regeneration of the Sensor chip surface between each injection was performed with 3 consecutive 5- μ l injections of 10 mM NaOH, 1 M NaCl.

LKB1 autophosphorylation and phosphorylation of MBP. 0.5 μ g of wild-type or catalytically inactive GST-LKB1 of the indicated complexes of LKB1 (Figure 8) that had been affinity purified on glutathione-Sepharose from 293 cells, was incubated in a 30- μ l reaction mixture containing 50 mM Tris-HCl (pH 7.5), 0.1% 2-mercaptoethanol, 0.1 mM EGTA, 10 mM manganese chloride, 0.5 μ M microcystin-LR, and 100 μ M [γ - 32 P]ATP (1000 cpm/pmol) in the presence of 3.3 μ g of bovine MBP. After incubation for 40 min at 30°C, the reactions were terminated by the addition of 8 μ l of sample Buffer. 30 μ l was electrophoresed on SDS-polyacrylamide gels, which were then dried and analysed by autoradiography to quantify LKB1 autophosphorylation, MBP and STRAD α phosphorylation. 5 μ l of each reaction was diluted in 45 μ l of 1 X SDS Sample Buffer. Of the resulting solution, 10 μ l were used for immunoblotting with the anti-GST (recognises LKB1), anti-Flag (recognises STRAD α and STRAD β) and anti-Myc (recognises MO25 α and MO25 β) antibodies. 30 μ l of the sample was used for immunoblotting with the T65-P MBP antibody.

Localisation studies. HeLa cells were cultured to 50% confluence on glass coverslips (no. 1.5) on 10-cm diameter dishes and transfected with a total of 2 μ g of a construct encoding wild-type GFP-LKB1 together with the indicated pCMV5 constructs using Effectene transfection reagent (Qiagen) according to the manufacturer's protocol. A duplicate set of dishes was used for each condition. The cells were washed with PBS 20 h post-transfection, and were fixed for 10 min in freshly prepared 4% (v/v) paraformaldehyde in PHEM Buffer (60 mM Pipes, 25 mM Hepes, 10 mM EGTA and 2 mM magnesium sulphate, pH 7.0). The cells were then washed twice with PBS and permeabilised with 1% (by vol) NP40 in PBS and blocked with 10% normal goat serum. The cells were immunolabelled with both the anti-

MO25 α antibody and anti-Flag antibody (to detect Flag-tagged STRAD α), washed in PBS and counter stained with Texas Red anti-sheep IgG and Cy5 anti-mouse IgG antibodies. The cells were imaged using a Zeiss LSM 510 META confocal microscope. Each channel was scanned independently to
 5 avoid cross talk (Multi-Tracking).

Northern Blot Analysis. A cDNA corresponding to human MO25 α (NCBI Acc, N. NM_016289, nucleotide residues 1550 to 2500), was ³²P-labelled by random priming using a Hi Prime DNA labelling kit (Roche). This probe was used to screen a Multiple Tissue Northern blot (Clontech, PT1200-1)
 10 using Rapid-Hyb Buffer (Amersham Pharmacia) according to the protocol provided by the manufacturer. Following autoradiography, the probe was stripped and the blot was then re-hybridised as above with a β -actin probe provided by the manufacturer.

References

- 15 Alessi, D.R., Caudwell, F.B., Andjelkovic, M., Hemmings, B.A. and Cohen, P. (1996) Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. *FEBS Lett*, **399**, 333-338.
- Anderson, S., Davie, D.N., Dahlbäck, H., Jörnvall, H. and Russell, D.W.
 20 (1989) Cloning, structure, and expression of the mitochondrial cytochrome-P- 450 sterol 26-hydroxylase, a bile-acid D biosynthetic enzyme. *J. Biol. Chem.*, **264**, 8222-8229.
- Harlow, E. and Lane, D. (1988) *Antibodies a Laboratory Manual*. Cold Spring Harbor Laboratory Publications, New York.
- 25 Lizcano, J.M., Deak, M., Morrice, N. and Alessi, D.R. (2002) Identification of the residues of S6K, SGK and PKB that are phosphorylated by NEK6. *Manuscript in Preparation*.

- Sanchez, I., Hughes, R.T., Mayer, B.J., Yee, K., Woodgett, J.R., Avruch, J., Kyriakis, J.M. and Zon, L.I. (1994) Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. *Nature*, **372**, 794-798.
- 5 Way, G., Morrice, N., Smythe, C. and O'Sullivan, A.J. (2002) Purification and identification of secernin, a novel cytosolic protein that regulates exocytosis in mast cells. *Mol Biol Cell*, **13**, 3344-3354.
- Woods, Y.L., Rena, G., Morrice, N., Barthel, A., Becker, W., Guo, S., Unterman, T.G. and Cohen, P. (2001) The kinase DYRK1A
10 phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. *Biochem J*, **355**, 597-607.
- Baas, A.F., Boudeau, J., Sapkota, G.P., Smit, L., Medema, R., Morrice, N.A., Alessi, D.R. and Clevers, H.C. (2003) Activation of the tumour suppressor kinase LKB1 by the STE20-like Pseudokinase STRAD. *EMBO J* **22**(12), 3062-3072
15
- Bardeesy, N., Sinha, M., Hezel, A.F., Signoretti, S., Hathaway, N.A., Sharpless, N.E., Loda, M., Carrasco, D.R. and DePinho, R.A. (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. *Nature*, **419**, 162-167.
- 20 Bidlingmaier, S., Weiss, E.L., Seidel, C., Drubin, D.G. and Snyder, M. (2001) The Cbk1p pathway is important for polarized cell growth and cell separation in *Saccharomyces cerevisiae*. *Mol Cell Biol*, **21**, 2449-2462.
- Boudeau, J., Deak, M., Lawlor, M.A., Morrice, N.A. and Alessi, D.R.
25 (2003a) Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability. *Biochem J*, **370**, 849-857.
- Boudeau, J., Kieloch, A., Alessi, D.R., Stella, A., Guanti, G. and Resta, N. (2003b) Functional analysis of LKB1/STK11 mutants and two

aberrant isoforms found in Peutz-Jeghers Syndrome patients. *Hum Mutat*, **21**, 172.

- Buchet-Poyau, K., Mehenni, H., Radhakrishna, U. and Antonarakis, S.E. (2002) Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK11IP gene on chromosome 2. *Cytogenet Genome Res*, **97**, 171-178.
- Collins, S.P., Reoma, J.L., Gamm, D.M. and Uhler, M.D. (2000) LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. *Biochem J*, **345 Pt 3**, 673-680.
- Dorland, S., Deegenars, M.L. and Stillman, D.J. (2000) Roles for the *Saccharomyces cerevisiae* SDS3, CBK1 and HYM1 genes in transcriptional repression by SIN3. *Genetics*, **154**, 573-586.
- Hemminki, A. (1999) The molecular basis and clinical aspects of Peutz-Jeghers syndrome. *Cell Mol Life Sci*, **55**, 735-750.
- Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Hoglund, P., Jarvinen, H., Kristo, P., Pelin, K., Ridanpaa, M., Salovaara, R., Toro, T., Bodmer, W., Olschwang, S., Olsen, A.S., Stratton, M.R., de la Chapelle, A. and Aaltonen, L.A. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature*, **391**, 184-187.
- Jenne, D.E., Reimann, H., Nezu, J., Friedel, W., Loff, S., Jeschke, R., Muller, O., Back, W. and Zimmer, M. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. *Nat Genet*, **18**, 38-43.
- Jishage, K.I., Nezu, J.I., Kawase, Y., Iwata, T., Watanabe, M., Miyoshi, A., Ose, A., Habu, K., Kake, T., Kamada, N., Ueda, O., Kinoshita, M., Jenne, D.E., Shimane, M. and Suzuki, H. (2002) Role of Lkb1, the

causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. *Proc Natl Acad Sci U S A*, **99**, 8903-8908.

Johnston, A.M., Naselli, G., Gonez, L.J., Martin, R.M., Harrison, L.C. and DeAizpurua, H.J. (2000) SPAK, a STE20/SPS1-related kinase that
 5 activates the p38 pathway. *Oncogene*, **19**, 4290-4297.

Jorgensen, P., Nelson, B., Robinson, M.D., Chen, Y., Andrews, B., Tyers, M. and Boone, C. (2002) High-Resolution Genetic Mapping With Ordered Arrays of *Saccharomyces cerevisiae* Deletion Mutants. *Genetics*, **162**, 1091-1099.

10 Karos, M. and Fischer, R. (1999) Molecular characterization of HymA, an evolutionarily highly conserved and highly expressed protein of *Aspergillus nidulans*. *Mol Gen Genet*, **260**, 510-521.

Karuman, P., Gozani, O., Odze, R.D., Zhou, X.C., Zhu, H., Shaw, R., Brien, T.P., Bozzuto, C.D., Ooi, D., Cantley, L.C. and Yuan, J. (2001) The
 15 Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. *Mol Cell*, **7**, 1307-1319.

Marignani, P.A., Kanai, F. and Carpenter, C.L. (2001) Lkb1 associates with brg1 and is necessary for brg1-induced growth arrest. *J Biol Chem*, **276**, 32415-32418.

20 Martin, S.G. and St Johnston, D. (2003) A role for *Drosophila* LKB1 in anterior-posterior axis formation and epithelial polarity. *Nature*, **421**, 379-384.

Miyamoto, H., Matsushiro, A. and Nozaki, M. (1993) Molecular cloning of a novel mRNA sequence expressed in cleavage stage mouse
 25 embryos. *Mol Reprod Dev*, **34**, 1-7.

Miyoshi, H., Nakau, M., Ishikawa, T.O., Seldin, M.F., Oshima, M. and Taketo, M.M. (2002) Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. *Cancer Res*, **62**, 2261-2266.

- Nakau, M., Miyoshi, H., Seldin, M.F., Imamura, M., Oshima, M. and Taketo, M.M. (2002) Hepatocellular carcinoma caused by loss of heterozygosity in *lkb1* gene knockout mice. *Cancer Res*, **62**, 4549-4553.
- 5 Nishigaki, K., Thompson, D., Yugawa, T., Rulli, K., Hanson, C., Cmarik, J., Gutkind, J.S., Teramoto, H. and Ruscetti, S. (2003) Identification and characterization of a novel Ste-20/GCK-related kinase, PAP kinase (PAPK). *J Biol Chem*.
- Nozaki, M., Onishi, Y., Togashi, S. and Miyamoto, H. (1996) Molecular
10 characterization of the *Drosophila* Mo25 gene, which is conserved among *Drosophila*, mouse, and yeast. *DNA Cell Biol*, **15**, 505-509.
- Resta, N., Stella, A., Susca, F.C., Di Giacomo, M., Forleo, G., Miccolis, I., Rossini, F.P., Genuardi, M., Piepoli, A., Grammatico, P. and Guanti, G. (2002) Two novel mutations and a new STK11/LKB1 gene
15 isoform in Peutz-Jeghers patients. *Hum Mutat*, **20**, 78-79.
- Rossi, D.J., Ylikorkala, A., Korsisaari, N., Salovaara, R., Luukko, K., Launonen, V., Henkemeyer, M., Ristimäki, A., Aaltonen, L.A. and Makela, T.P. (2002) Induction of cyclooxygenase-2 in a mouse
20 model of Peutz-Jeghers polyposis. *Proc Natl Acad Sci U S A*, **99**, 12327-12332.
- Sanna, M.G., da Silva Correia, J., Luo, Y., Chuang, B., Paulson, L.M., Nguyen, B., Deveraux, Q.L. and Ulevitch, R.J. (2002) ILPIP, a novel
anti-apoptotic protein that enhances XIAP-mediated activation of JNK1 and protection against apoptosis. *J Biol Chem*, **277**, 30454-
25 30462.
- Sapkota, G.P., Boudeau, J., Deak, M., Kieloch, A., Morrice, N. and Alessi, D.R. (2002a) Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on

- LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome. *Biochem J*, **362**, 481-490.
- Sapkota, G.P., Deak, M., Kieloch, A., Morrice, N., Goodarzi, A.A., Smythe, C., Shiloh, Y., Lees-Miller, S.P. and Alessi, D.R. (2002b) Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366. *Biochem J*, **368**, 507-516.
- Sapkota, G.P., Kieloch, A., Lizcano, J.M., Lain, S., Arthur, J.S., Williams, M.R., Morrice, N., Deak, M. and Alessi, D.R. (2001) Phosphorylation of the protein kinase mutated in Peutz-Jeghers Cancer Syndrome, LKB1/STK11, at Ser431 by p90RSK and cAMP-dependent protein kinase, but not its farnesylation at Cys433, is essential for LKB1 to suppress cell growth. *J Biol Chem*, **276**, 19469-19482.
- Smith, C.M., Radzio-Andzelm, E., Madhusudan, Akamine, P. and Taylor, S.S. (1999) The catalytic subunit of cAMP-dependent protein kinase: prototype for an extended network of communication. *Prog Biophys Mol Biol*, **71**, 313-341.
- Smith, D.P., Rayter, S.I., Niederlander, C., Spicer, J., Jones, C.M. and Ashworth, A. (2001) LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1. *Hum Mol Genet*, **10**, 2869-2877.
- Songyang, Z., Fanning, A.S., Fu, C., Xu, J., Marfatia, S.M., Chishti, A.H., Crompton, A., Chan, A.C., Anderson, J.M. and Cantley, L.C. (1997) Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. *Science*, **275**, 73-77.
- Tamari, M., Daigo, Y. and Nakamura, Y. (1999) Isolation and characterization of a novel serine threonine kinase gene on chromosome 3p22-21.3. *J Hum Genet*, **44**, 116-120.

- Tiainen, M., Vaahtomeri, K., Ylikorkala, A. and Makela, T.P. (2002) Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1). *Hum Mol Genet*, **11**, 1497-1504.
- 5 Tiainen, M., Ylikorkala, A. and Makela, T.P. (1999) Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. *Proc Natl Acad Sci U S A*, **96**, 9248-9251.
- Watts, J.L., Morton, D.G., Bestman, J. and Kemphues, K.J. (2000) The C. elegans par-4 gene encodes a putative serine-threonine kinase required for establishing embryonic asymmetry. *Development*, **127**,
 10 1467-1475.
- Ylikorkala, A., Rossi, D.J., Korsisaari, N., Luukko, K., Alitalo, K., Henkemeyer, M. and Makela, T.P. (2001) Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. *Science*, **293**, 1323-1326.
- 15 Yoo, L.I., Chung, D.C. and Yuan, J. (2002) LKB1 A master tumour suppressor of the small intestine and beyond. *Nat Rev Cancer*, **2**, 529-535.

Example 2: Complexes between the LKB1 tumour suppressor, Strada α/β and Mo25 α/β are upstream kinases in the AMP-activated protein kinase cascade

20

The AMP-activated protein kinase (AMPK) cascade is a sensor of cellular energy charge that acts as a "metabolic master switch" and inhibits cell proliferation. Activation requires phosphorylation within the activation
 25 loop (Thr-172) by upstream kinases (AMPKKs) that have not been identified. Recently we identified three related protein kinases acting upstream of the yeast homologue of AMPK, which do not have obvious mammalian homologues. However, a closely related mammalian kinase is

LKB1, for which no physiological substrates have been identified. LKB1 acts as a tumour suppressor and is mutated in human Peutz-Jeghers syndrome. We show in Example 1 that it exists as a complex with two accessory subunits, STRAD α/β and MO25 α/β .

5

We report that: (i) two AMPKK activities purified from rat liver contain LKB1, STRAD α and MO25 α , and can be immunoprecipitated using anti-LKB1 antibodies; (ii) both endogenous and recombinant complexes of LKB1, STRAD α/β and MO25 α/β activate AMPK via phosphorylation of
 10 Thr-172, (iii) catalytically active LKB1 and STRAD α or STRAD β and MO25 α or MO25 β are required for full activity; (iv) the drugs AICA riboside and phenformin do not activate AMPK in HeLa cells (which lack LKB1), but this can be restored by stably expressing wild type, but not catalytically inactive, LKB1 in these cells.

15

These results provide the first description of a physiological substrate for the LKB1 tumour suppressor and suggest that it functions as an upstream regulator of AMPK. Our findings indicate that the formation of tumours in Peutz-Jeghers syndrome could result from deficient activation of AMPK as
 20 a consequence of LKB1 inactivation.

Results

Resolution of two AMPKKs from rat liver extracts

While experimenting with different conditions to optimise recovery at the Q-Sepharose step of our previous purification protocol for AMPKK [14],
 25 we found that we were able to resolve two peaks of activity (Fig. 13A). Because the second peak appears to correspond to the AMPKK originally purified [14], we refer to it as AMPKK1, with the first peak eluting from the column termed AMPKK2. The AMPKK assays in Fig. 13A were

conducted using as a substrate a bacterially expressed glutathione-S-transferase (GST) fusion of the catalytic domain of rat AMPK α 1. This is more convenient than the native rat liver AMPK heterotrimer used previously [14] because the AMPK α 1 catalytic domain is already
 5 completely dephosphorylated and therefore inactive when expressed in bacteria. It is also possible to carry out the assays with the substrate bound to glutathione-Sepharose beads, allowing any endogenous AMPK in the AMPKK fraction that might otherwise interfere to be washed away. On size exclusion chromatography on Sephacryl S-200, AMPKK1 and
 10 AMPKK2 eluted as proteins of large but distinct size. By comparison with standards, the Stokes radii for AMPKK1 and AMPKK2 were estimated as 5.2 and 5.7 nm respectively. Ca²⁺ and calmodulin stimulated neither AMPKK1 nor AMPKK2, and neither were immunoprecipitated using an antibody against CaMKK (not shown).

15 *AMPKK1 and AMPKK2 both contain LKB1, STRAD α and MO25 α*

To examine whether either of these two fractions might contain LKB1, we probed blots of fractions across the Q-Sepharose chromatography using antibodies against LKB1, STRAD α and MO25 α (Fig. 13B-D). This revealed that the activity of AMPKK2 correlated with the presence of the
 20 ~50 kDa polypeptide of LKB1 (~50 kDa) as well as those of STRAD α (~45/48 kDa) and Mo25 α (~40 kDa) in fractions 18-22.~ STRAD α was detected as a doublet as reported previously [30]; the reason for this behaviour is not known. We did not obtain any signal of the correct molecular mass in these fractions using anti-MO25 β antibody (not shown),
 25 consistent with our observations that the MO25 β isoform is not expressed in mouse liver (Example 1). We also obtained a faint signal for LKB1 and STRAD α in fractions 27-29 that contained AMPKK1, but at this loading MO25 α was below the limit of detection in these fractions. However, the

presence of LKB1, STRAD α and MO25 α in AMPKK1 was confirmed by analysing a higher loading of fractions 26-30 (Fig. 12E-G). An interesting finding was that the LKB1 polypeptide migrated with a slightly faster mobility in AMPKK1 compared with AMPKK2: this is evident by inspection of Fig. 13B (see also Figs. 14B and 14D).

AMPKK activity can be immunoprecipitated from AMPKK1 and AMPKK2
Using anti-LKB1 antibody but not a pre-immune control IgG, we were able to immunoprecipitate AMPKK activity from both AMPKK1 and AMPKK2. Fig. 14A shows results of an experiment where the amount of kinase kinases was limiting and the antibody was in excess, and shows that we were able to remove >80% of the activity from the peak fractions containing AMPKK1 and AMPKK2 by immunoprecipitating with anti-LKB1 antibody, while no activity was removed using a pre-immune control immunoglobulin. We could remove >95% of the AMPKK activity of a recombinant GST-tagged LKB1-STRAD α -MO25 α complex (see next section) under the same conditions. The small amount of activity remaining in the supernatants of the AMPKK1 and AMPKK2 fractions could be accounted for by the fact that the immunoprecipitation was not quantitative in these cases, with about 20% of the LKB1 polypeptide remaining in the supernatant (Fig. 14B).

Due to the small amount of AMPKK1 and AMPKK2 used in this experiment, it proved difficult to analyse the pellets for AMPKK activity and the presence of the other polypeptides. We therefore repeated the experiment with more kinase kinase and less antibody (the amount of antibody was now limiting) and analysed the pellets only. This showed that we could recover almost as much AMPKK activity in the pellet from the peak fractions containing AMPKK1 and AMPKK2 as we could from the recombinant LKB1-STRAD α -MO25 α complex, with no activity being

recovered using pre-immune control immunoglobulin (Fig. 14C). Western blotting of the AMPKK1 and AMPKK2 pellets showed that they contained LKB1, STRAD α and MO25 α , although the STRAD α doublet was very faint in the AMPKK1 pellet (Fig. 14D).

5 *Recombinant LKB1-STRAD-MO25 complexes activate AMPK α 1 catalytic domain in cell-free assays*

To examine whether LKB1 activated AMPK on its own or whether the accessory subunits STRAD α/β and Mo25 α/β were required, we expressed GST-tagged LKB1, FLAG-tagged STRAD α/β and *myc*-tagged Mo25 α/β in
 10 various combinations in HEK-293T cells, and purified the complexes on glutathione-Sepharose. We also used a GST-tagged kinase-inactive mutant of LKB1 (D194A), and a plasmid expressing GST alone, as controls. The purified complexes were incubated with the AMPK α 1 catalytic domain in the presence of MgATP, and activation of the catalytic domain as well as
 15 phosphorylation of Thr172 (using a phosphospecific anti-pT172 antibody) was measured. Fig. 15A shows that LKB1 alone did not significantly increase the activity, or phosphorylation of Thr172, of the AMPK α 1 catalytic domain above the basal activity observed in the presence of GST alone (compare lanes 1 and 14). The same result was obtained with LKB1
 20 that had been co-expressed with MO25 α or MO25 β (lanes 4 and 5), which was expected as these proteins do not interact with LKB1 in the absence of STRAD α/β (Example 1). An LKB1-STRAD α complex did give a small but significant activation, and Thr172 phosphorylation, of the AMPK α 1 catalytic domain above the basal value (compare lanes 1 and 2). However
 25 to produce a large activation and phosphorylation of the AMPK α 1 catalytic domain, a heterotrimeric complex containing LKB1, STRAD α or STRAD β , and MO25 α or MO25 β was required (lanes 6 to 9). With the heterotrimeric complexes the degree of activation was in the order LKB1-STRAD α -

MO25 α > LKB1-STRAD α -MO25 β \approx LKB1-STRAD β -MO25 α > LKB1-STRAD β -MO25 β . Importantly, the ability of LKB1-STRAD-MO25 complexes to activate AMPK α 1 was entirely dependent on LKB1 catalytic activity, because complexes of a catalytically inactive mutant of LKB1 (D194A) with the various combinations of STRAD α/β and MO25 α/β (lanes 10-13), were unable to activate or phosphorylate AMPK α 1. The degree of activation obtained with these various complexes of wild type LKB1 correlated well with the phosphorylation of Thr-172. Probing with an antibody against the whole AMPK α 1 catalytic domain (labelled GST- α 1-KD in Fig. 15A) confirmed that the loading was uniform in these samples. The bottom three panels in Fig. 15A confirm that the relevant STRAD and MO25 subunit co-precipitated with LKB1 when DNAs encoding these subunits had been co-transfected. When STRAD α was co-expressed with LKB1 in the absence of an MO25 subunit, the amount of STRAD α subunit co-precipitated with LKB1 was reduced (lanes 2 and 3). This is consistent with previous findings that the presence of an MO25 subunit stabilizes LKB1-STRAD complexes (Example 1).

Fig. 15B provides evidence that Thr-172 was the only site on the AMPK α 1 catalytic domain phosphorylated by the LKB1-STRAD α -MO25 α complex. When the two proteins were incubated together in the presence of [γ - 32 P]ATP, the wild type AMPK α 1 catalytic domain became 32 P-labelled, but a Thr172 \rightarrow Ala mutant of the AMPK α 1 catalytic domain did not.

AMPKK1, AMPKK2 and recombinant LKB1-STRAD-MO25 complexes also activate heterotrimeric AMPK complexes

Although most of the AMPKK assays in this study were conducted using the AMPK α 1 catalytic domain as substrate, Fig 16 shows that AMPKK1,

AMPKK2 and the recombinant GST-LKB1:STRAD α :MO25 α complex also activated heterotrimeric AMPK complexes. Plasmids encoding the α 1, β 1 and γ 1 or α 2, β 1 and γ 1 subunits of AMPK were co-expressed in CCL13 cells and purified by means of a *myc* tag on the α subunits. The recombinant AMPK complexes bound to protein G-Sepharose beads were incubated with MgATP and AMPKK1, AMPKK2 or GST-LKB1:STRAD α :MO25 α , the upstream kinase washed away and the activity of the AMPK complexes determined. Figure 16 shows that both the α 1 β 1 γ 1 and α 2 β 1 γ 1 complexes were activated by all three upstream kinase preparations, and that this correlated with the phosphorylation of Thr-172 on the α subunits, shown using the anti-pT172 antibody (which recognises phosphorylated Thr-172 on both α 1 and α 2). The blot using anti- α 1 and - α 2 antibodies confirms uniform loading (note that a stronger signal is always obtained with the anti- α 2 than the anti- α 1 antibody, even when the protein loading is the same). Although the activity of AMPKK2 used was 3.5 times higher than that of AMPKK1 and only 30% lower than that of GST-LKB1-STRAD α :MO25 α in terms of its ability to activate the AMPK α 1 catalytic domain, AMPKK2 appeared to be much less effective at activating the α 1 β 1 γ 1 complex. These differences were less obvious using the α 2 β 1 γ 1 complex as the substrate.

Endogenous LKB1 that activates AMPK can be immunoprecipitated from 293 cells but not HeLa cells

Fig. 17 shows that an activity that activated the AMPK α 1 catalytic domain and phosphorylated Thr-172 could be immunoprecipitated from untransfected HEK-293T cell extract using anti-LKB1 antibody (lane 1), but not a pre-immune control immunoglobulin (lane 2). As reported previously [30, Example 1], immunoprecipitation of endogenous LKB1

resulted in the co-precipitation of STRAD α and MO25 α (lane 1). As a further control, we employed normal HeLa cells as an LKB1 null cell line, as it is known that LKB1 is not expressed in these cells [23]. Consistent with this, no LKB1, STRAD α and MO25 α subunits or AMPKK activity
 5 was immunoprecipitated from the same amount of HeLa cell extract protein using anti-LKB1 antibody (lane 3). However, AMPKK activity and Thr-172 phosphorylation, as well as detectable STRAD α and MO25 α subunits, were recovered following immunoprecipitation of LKB1 from HeLa cells [34], that stably express wild type LKB1 [32] (lane 5). In cells expressing a
 10 catalytically-inactive mutant of LKB1, the LKB1, STRAD α and MO25 α polypeptides were recovered by immunoprecipitation using anti-LKB1 antibody, but no AMPKK activity (lane 7). Although the LKB1 polypeptide was over-expressed to a large extent in the HeLa cells compared to the endogenous levels observed in 293 cells (Fig 14, compare lanes 1 and 5), it
 15 is clear that the amount of STRAD α and MO25 α in the cells is limiting in these cells. There was a lower amount of AMPKK activity and Thr-172 phosphorylation, as well as co-precipitating STRAD α and MO25 α , in HeLa cells expressing LKB1 than in 293 cells, even though LKB1 itself was over-expressed. The AMPKK activity in the immunoprecipitates from
 20 293 cells and HeLa cells expressing wild type LKB1 correlated with the levels of STRAD α and MO25 α in the complex rather than with the levels of LKB1. This further emphasises the essential nature of the STRAD and MO25 subunits in enhancing the AMPKK activity of LKB1.

Expression of LKB1 restores activation of AMPK in HeLa cells

25 We have previously found (unpublished results) that, although AMPK is expressed in HeLa cells, it is not activated by the drugs 5-aminoimidazole-4-carboxamide (AICA) riboside and metformin, which readily activate the kinase in other cell types [33,34]. As HeLa cells do not express LKB1 [23]

this could provide a potential explanation for this anomaly. To examine whether expression of recombinant LKB1 might restore the ability of HeLa cells to respond to these drugs, we used the HeLa cell that stably express wild type LKB1, or the catalytically inactive mutant [32], as well as a control HeLa cell line not expressing LKB1. In these experiments we used phenformin, which is a close relative of metformin that we have found to activate AMPK more rapidly and more potently than metformin in other cell types. Fig. 18A shows that neither AICA riboside nor phenformin activated AMPK in control HeLa cells. However, in cells expressing wild type LKB1, but not the kinase-inactive mutant, both AICA riboside and phenformin caused a robust activation of AMPK. This correlated with the phosphorylation of Thr-172 on AMPK α , shown by probing with the anti-pT172 antibody (Fig. 18B), and also with the phosphorylation of a downstream target of AMPK, acetyl-CoA carboxylase (ACC), shown by probing with a phosphospecific antibody against Ser-79, the primary AMPK site on that protein (anti-pACC, Fig. 18C). Interestingly, stable expression of wild type LKB1 in the HeLa cells caused a small but reproducible degree of up-regulation of expression of AMPK α 1 and a marked down-regulation of expression of ACC (not shown). Because the expression of these proteins was not uniform in these cells, in order to accurately quantitate their phosphorylation status we simultaneously probed single blots of lysates using either anti-pT172 and anti- α 1/ α 2 antibodies (to detect Thr-172 phosphorylation and total AMPK α), or with anti-pACC and avidin (to detect Ser-79 phosphorylation and total ACC). The two probing reagents used in each of these dual-labelling protocols were labelled with different fluorescent dyes emitting in different regions of the infra-red (IR) spectrum, and the results were quantified in two separate channels using an IR laser scanner. In Fig. 18B and 18C the results are expressed as ratios of the signal obtained using the phosphospecific antibody to the signal obtained

for the total protein. This method corrects for different levels of expression of the proteins, and reveals that there was a good correlation between activation of AMPK and phosphorylation of Thr-172. There was also a correlation with phosphorylation of ACC, although in this case AICA
 5 riboside appeared to have a larger effect than phenformin.

Discussion

Our results provide strong evidence that LKB1-STRAD-MO25 complexes represent the major upstream kinase activities acting on AMPK. The key evidence may be summarised as follows:

10

1. During previous extensive efforts over 10 years to purify from rat liver extracts activities that activate dephosphorylated AMPK, ([14] and subsequent unpublished work), we have not detected any activities other than AMPKK1 and AMPKK2, at least under the assay conditions used.
- 15 2. Both AMPKK1 and AMPKK2 contained LKB1, STRAD α and MO25 α that were detectable by Western blotting and that correlated with the activity (Fig.13).
3. Crucially, the ability of the AMPKK1 and AMPKK2 fractions to activate the AMPK α 1 catalytic domain was almost completely
 20 eliminated by immunoprecipitation with anti-LKB1 antibody but not a control immunoglobulin. Activity was detected in the anti-LKB1 immunoprecipitates, together with the LKB1, STRAD α and MO25 α polypeptides, but not in the control immunoprecipitates (Fig. 14).
4. The AMPKK activity in AMPKK1 and AMPKK2 was not a
 25 contaminant that co-precipitated with anti-LKB1 antibody, because recombinant complexes of GST-LKB1, STRAD and MO25 expressed in 293 cells and purified on glutathione-Sepharose activated the AMPK α 1 catalytic domain efficiently, and phosphorylated Thr-172 (Fig. 15). This

activity was dependent on the integrity of the LKB1 catalytic domain, because complexes formed from catalytically inactive LKB1 with a STRAD and MO25 subunit failed to activate or phosphorylate AMPK. Phosphorylation of the $\alpha 1$ catalytic domain appeared to occur exclusively at Thr-172, because the wild type AMPK $\alpha 1$ catalytic domain, but not a T172A mutant, could be phosphorylated using [γ - 32 P]ATP and the GST-LKB1-STRAD α -MO25 α complex.

5. Although most of the experiments in this paper were conducted using the bacterially expressed AMPK $\alpha 1$ catalytic domain as substrate, AMPKK1, AMPKK2 and recombinant LKB1-STRAD α -MO25 α complexes also activated heterotrimeric AMPK complexes ($\alpha 1\beta 1\gamma 1$ and $\alpha 2\beta 1\gamma 1$) efficiently, and phosphorylated them at Thr-172 on the α subunits (Fig. 16).
6. HeLa cells do not express LKB1 (Fig. 17) and therefore represent a natural "knock-out" cell line. The drugs AICA riboside and phenformin, which activate AMPK in other cell types via distinct mechanisms [33,34], did not activate AMPK in HeLa cells. However, in cells stably transfected with DNA that expressed wild type LKB1 (but not a catalytically-inactive mutant) from an inducible promoter, the ability of AICA riboside and phenformin to activate AMPK, to phosphorylate Thr-172 on the AMPK α subunit, and to cause phosphorylation of a downstream target (ACC) was restored (Fig. 18). Although phenformin caused a larger activation of AMPK and phosphorylation of Thr-172 than AICA riboside in these cells, the reverse was true for phosphorylation of ACC. The reason for this is not known, but one possibility is that the two agents are differentially activating distinct pools of AMPK at different subcellular locations.

Although the LKB1 polypeptide was over-expressed in the HeLa cells, the degree of AMPK activation and the amount of STRAD α and MO25 α co-precipitating with LKB1 was actually lower than in 293 cells (Fig. 17). This strongly supports the findings in Fig. 15 showing that both accessory subunits are necessary to enhance the ability of LKB1 to activate AMPK, and also show that the active form of LKB1 is not being over-expressed compared to 293 cells. The results in the HeLa cells suggest that LKB1 and its accessory subunits are both necessary and sufficient for activation of AMPK in intact cells. However, they do not formally prove this, because if there are other kinases acting upstream of AMPK, it is conceivable that these are also deleted in HeLa cells. Our numerous attempts at purification of AMPKKs from rat liver extracts have only ever detected AMPKK1 and AMPKK2, which now appear to both represent LKB1-STRAD α -MO25 α complexes. However, as in any protein purification protocol the recovery of activity is not quantitative, and we cannot rule out the possibility that other upstream kinases could have been missed. We would also not detect any upstream kinase that was not active under the assay conditions used. For example, the assays were conducted in the presence of EGTA, so we would not detect any Ca²⁺-dependent protein kinases. We have already shown that a Ca²⁺/calmodulin-dependent protein kinase kinase (CaMKK) from pig brain can activate AMPK in cell-free assays [17], although it was much more effective at activating calmodulin-dependent protein kinase I, and there is no evidence that it phosphorylates AMPK *in vivo*.

Both AMPKK1 and AMPKK2 appear to contain LKB1, STRAD α and MO25 α , and thus it is not clear at present why they resolve on Q-Sepharose chromatography. One interesting difference was that the LKB1 polypeptide in AMPKK1 migrated significantly faster on SDS-PAGE than that in AMPKK2 (Figs. 13 and 14). LKB1 is known to be phosphorylated at up to

eight sites, and it is also farnesylated at Cys-433 near the C-terminus [34-37]. We therefore suspect that the difference in mobility may be due to a difference in covalent modification. Another difference between AMPKK1 and AMPKK2 was their Stokes radii estimated by size exclusion chromatography (5.7 versus 5.2 nm respectively). We previously estimated the Stokes radius for AMPKK1 to be 5.6 nm, and combining this with a sedimentation coefficient of 8.5S obtained by glycerol gradient centrifugation had obtained an estimate of 195 kDa for the molecular mass [14]. Assuming that AMPKK1 and AMPKK2 have a similar shape, this would yield a molecular mass of about 175 kDa for AMPKK2, which is reasonably close to the calculated molecular mass (not counting covalent modifications) of a 1:1:1 LKB1-STRAD α -MO25 α complex of 140 kDa. Although we cannot rule out the possibility that AMPKK1 contains an additional associated protein, it is possible that differences in covalent modification between AMPKK1 and AMPKK2 might affect the shape of the complex and hence the Stokes radius. Consistent with the behaviour of the AMPKK1 and AMPKK2 complexes on size exclusion chromatography, endogenous LKB1 was previously shown to migrate on gel filtration with an apparent molecular mass of 150-250 kDa, in marked contrast to LKB1 expressed in *E. coli*, which had an apparent molecular mass of 50 kDa [38]. Our present results confirm, using a probable physiological substrate, previous findings using an artificial substrate (myelin basic protein) that a STRAD subunit stimulates the kinase activity of LKB1 [30], and that the MO25 subunit stimulates the activity further, probably by stabilizing the LKB1-STRAD complex (Example 1). No AMPKK activity was obtained with recombinant LKB1 unless a STRAD subunit was also expressed, and the activity was increased substantially by the additional presence of an MO25 subunit (Fig. 15). It was also noticeable that the amount of STRAD α and STRAD β that co-precipitated with LKB1 was greatly

enhanced by the co-expression of MO25 α or MO25 β (Fig. 15) consistent with our previous findings (Example 1). The exact mechanism by which the STRAD and MO25 subunits activate LKB1 remains unclear, but these accessory subunits introduce scope for additional regulation of the kinase.

5 It is already known that LKB1 phosphorylates STRAD α at 2 distinct sites [30], and that STRAD α and MO25 α form a complex that retains LKB1 in the cytoplasm (Example 1). It is also interesting to note that both AMPK and its upstream kinase are heterotrimers.

10 Does activation of AMPK explain the ability of LKB1 to act as a tumour suppressor and to arrest cell growth and proliferation? This certainly seems plausible, because apart from the fact that AMPK is a general inhibitor of biosynthesis [1,2], there is also accumulating evidence that it can regulate progress through the cell cycle. For example, activation of AMPK inhibits
15 proliferation of HepG2 cells by stabilizing p53 [13], and reduces the level of the RNA binding protein HuR in the cytoplasm, decreasing the stability of mRNAs encoding cyclins A and B1 [12]. Interestingly, expression of LKB1 in G361 cells that do not express the kinase causes an arrest in G1 phase that is associated with an induction of p21 and is dependent on p53
20 [23,24].

Another exciting possibility is that LKB1-STRAD-MO25 complexes might also act as upstream kinases for other protein kinases, in the same manner that PDK1 phosphorylates threonine residues in the activation loop of a number of kinases of the "AGC" sub-family [39]. A dendrogram showing
25 the relationships between catalytic domain sequences of 518 human protein kinases encoded in the human genome [40] shows that the AMPK α 1 and AMPK α 2 subunits lie on a small sub-branch also containing eight other protein kinases (NuaK1, NuaK2, BrsK1, BrsK2, SIK, QIK, QSK and MELK; see [41] for details), most of which have either not been studied

previously or about which very little is known. An alignment of the activation loop sequences of these kinases is shown in Fig. 19, together with those of the close relative "AGC" sub-family catalytic C α subunit of cyclic AMP-dependent protein kinase (PKA α , which can be phosphorylated in the activation loop by autophosphorylation) and the α isoform of protein kinase C (PKC α), which is activated by phosphorylation in the activation loop by PDK1. Also included in Fig. 19 are the activation loop sequences of the *Arabidopsis thaliana* (AtSnRK1 α 1, AtSnRK α 2) and *Saccharomyces cerevisiae* (ScSnf1) homologues of AMPK, both of which have been shown previously to be activated by rat liver AMPKK in cell-free assays [42,43]. All of the sequences are well conserved on the C-terminal side of the threonine residue that is the target for phosphorylation, but the AMPK/Snf1 subfamily are more highly conserved on the N-terminal side between the invariant "DFG" motif and the threonine residue. Sequence features that are conserved in the AMPK/SNF1 subfamily but not in the "AGC" family include pairs of hydrophobic residues at the -3, -2 and the -9, -8 positions. NuaK1 and NuaK2 and the human, plant and yeast AMPK/SNF1 kinases also have a conserved "LSN" motif at the -12 to -10 positions. It remains to be determined whether the other human kinases in the AMPK sub-family are activated by phosphorylation of the equivalent activation loop threonine residue, and whether they might also be downstream targets for LKB1/STRAD/MO25 complexes. If this is the case, these other kinases could mediate some of the tumour suppressor functions of LKB1. Since the catalytic domains in this sub-family are closely related, but the other regions tend to be more variable, one could speculate that these kinases may be activated by different stresses or other stimuli via phosphorylation by LKB1/STRAD/MO25 complexes, and together may mediate the diverse cellular effects that are triggered by LKB1. It is also possible that they might share some common downstream targets with AMPK.

Conclusions

Our results provide strong evidence, both in cell-free assays and in intact cells, that complexes between LKB1, STRAD α/β and MO25 α/β constitute the long sought after upstream kinases that activate AMPK via phosphorylation at Thr-172 in the activation loop. Because it is already known that pharmacological activation of AMPK causes a general inhibition of biosynthesis, as well as a p53-dependent arrest in G1 phase, activation of AMPK by LKB1 might explain, at least in part, the ability of the latter to act as a tumour suppressor. LKB1 may also act as an upstream kinase for other members of the AMPK/SNF1 sub-family of protein kinases.

Material and methods

Materials, proteins and antibodies

Protein G-Sepharose and prepacked Q-Sepharose columns were from Amersham Pharmacia Biotech, UK. GST-AMPK α 1-catalytic domain was expressed in *E. coli* and purified as described previously [44]. Sheep antibodies against the α 1 and α 2 subunits of AMPK [45], human LKB1, MO25 α and MO25 β (Example 1), and phosphospecific antibody against the Thr-172 site on the AMPK α subunit (anti-pT172) [46] were described previously. Sheep antibody against AMPK α 1-catalytic domain was raised against the peptide CDPMKRATpIKDIRE (cysteine + residues 252-264 of rat α 1, Tp = phosphothreonine) using methods described for anti-pT172 [46]. Although designed as a phosphospecific antibody, it recognizes GST-AMPK α 1-catalytic domain expressed in bacteria and recognition is not affected by protein phosphatase treatment. The monoclonal antibody against STRAD α was described previously [30]. Sources of other materials and proteins were described previously [14].

Enzyme assays

AMPK [14] and AMPKK [34] were assayed, and units defined, as described previously. Rapid lysis of cells for AMPK assays was as described previously [47]. Assays were carried out in triplicate and results are
 5 expressed as mean \pm standard deviation.

Purification of AMPKK1 and AMPKK2

AMPKK was purified to the Blue-Sepharose stage as described previously [14]. The flow-through from this column was adjusted to 160 mM NaCl by dilution in buffer A (50 mM Hepes, 10% (w/v) glycerol, 0.02% (w/v) Brij-
 10 35, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM benzamidine, 0.1 mM PMSF, 1 μ g/ml soybean trypsin inhibitor), and applied to a high performance Q-Sepharose HiLoad 16/10 column in buffer A plus 160 mM NaCl at 3 ml/min. The column was washed in buffer A plus 160 mM NaCl until the A_{280} was <0.05 , and AMPKK activity was then eluted with a linear
 15 gradient (120 ml) from 160-400 mM NaCl in buffer A.

Expression of recombinant LKB1 complexes in HEK-293T cells

Various combinations of GST-tagged LKB1, FLAG-tagged STRAD α or STRAD β , and myc-tagged MO25 α or MO25 β were expressed in HEK-293T cells and the complexes purified on glutathione-Sepharose as
 20 described in Example 1.

Phosphorylation of GST- α 1 catalytic domain using [γ - 32 P]ATP

GST- α 1 catalytic domain (50 μ g/ml), either wild type or a T172A mutant [44] was incubated for 30 min at 30°C with 5 mM MgCl₂ and [γ - 32 P]ATP
 25 (200 μ M; \sim 750 cpm/pmole) in the presence or absence of the GST-LKB1:STRAD α :MO25 α complex (20 units/ml). The reaction was

terminated by the addition of SDS sample buffer (Invitrogen), the polypeptides resolved by SDS-PAGE and the dried gel subjected to autoradiography.

Preparation of recombinant AMPK heterotrimers

- 5 Plasmids encoding *myc*- α 1, β 1 and γ 1 were co-expressed in CCL13 cells [45], and cells harvested by the rapid lysis method [47]. Lysates were immunoprecipitated with anti-*myc* antibody and resuspended in 50mM NaHEPES, 1 mM dithiothreitol, 0.02% (w/v) Brij-35, pH 7.5.

Immunoprecipitation of endogenous LKB1

- 10 Immunoprecipitation of endogenous LKB1 using anti-human antibody and protein G-Sepharose is described in Example 1. The kinase kinase assays were conducted using GST- α 1-catalytic domain as substrate in shaking incubators as described previously for immunoprecipitate assays of AMPK [47].

15 *HeLa cells expressing LKB1*

The generation of HeLa cells stably expressing inducible (Tet-ON) wild type or kinase-inactive mutant LKB1, and conditions for their culture, has been described previously [32].

Protein analysis and electrophoresis

- 20 Protein concentration was determined using the dye-binding method of Bradford [48]. SDS-PAGE was achieved using precast Bis-Tris 4–12% gradient polyacrylamide gels, in the MOPS buffer system (Invitrogen), except for analysis of acetyl-CoA carboxylase, where pre-cast 3–8% Tris-acetate gels (Invitrogen) were used. Proteins were transferred to
25 nitrocellulose membranes (BioRad) using the Xcell II Blot Module (Invitrogen).

Detection of Western blots by infra-red imaging

To analyse phosphorylation of ACC, samples were analysed by SDS-PAGE, transferred to nitrocellulose (BioRad) and incubated in Odyssey™ Blocking buffer containing 0.2% Tween-20 for 1 h. Anti-pACC antibody (1.46 µg/ml in blocking buffer) was then added and left shaking for 1 h. The membranes were washed 6 x 5 min with TBS (10 mM Tris-HCl, pH 7.4, 0.5M NaCl) plus Tween-20 (0.2%). The membranes were immersed in blocking buffer containing 0.2% Tween-20 and 1 µg/ml anti-sheep IgG conjugated to IR dye 680 (Molecular Probes, Leiden, The Netherlands) and 1 µg/ml streptavidin conjugated to IR Dye 800 (Rockland Inc., Philadelphia, PA) and left shaking for 1 h, protected from light. The membranes were then washed 6 x 5 min using TBS-Tween (0.2%) and 1 x 5 min in PBS. The membranes were scanned in two different channels using the Odyssey™ IR imager, the results quantified using Odyssey™ software and expressed as a ratio of the signal obtained with the pACC antibody to that obtained with streptavidin. Analysis of phosphorylation of GST-α1 catalytic domain was similar except that the 4-12% Bis-Tris gels were used, and the membranes were simultaneously probed for 1 h with the sheep anti-pT172 and anti-AMPKα1-catalytic domain antibodies, directly labelled with the IR dye 680 and IR Dye 800 respectively, according to manufacturers' instructions.

References

1. Hardie, DG, Scott, JW, Pan, DA, Hudson, ER: **Management of cellular energy by the AMP-activated protein kinase system.** *FEBS Lett.* 2003 546, 113-120.
2. Hardie, DG, Hawley, SA: **AMP-activated protein kinase: the energy charge hypothesis revisited.** *BioEssays* 2001, 23: 1112-1119.

3. Coven, DL, Hu, X, Cong, L, Bergeron, R, Shulman, GI, Hardie, DG, Young, LH: **Physiologic role of AMP-activated protein kinase (AMPK) in the heart: graded activation during exercise.** *Am J Physiol Endocrinol Metab* 2003,
- 5 4. Horman, S *et al.*: **Activation of AMP-activated protein kinase leads to the phosphorylation of Elongation Factor 2 and an inhibition of protein synthesis.** *Current Biol.* 2002, 12: 1419-1423.
5. Krause, U, Bertrand, L, Hue, L: **Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes.** *Eur. J. Biochem.* 2002, 269: 3751-3759.
- 10 6. Bolster, DR, Crozier, SJ, Kimball, SR, Jefferson, LS: **AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mTOR signaling.** *J. Biol. Chem.* 2002, 277: 23977-23980.
- 15 7. Meisse, D, Van de Castele, M, Beauloye, C, Hainault, I, Kefas, B, Rider, M, Foufelle, F, Hue, L: **Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells.** *FEBS Lett.* 2002, 526: 38-42.
- 20 8. Kefas, BA, Cai, Y, Ling, Z, Heimberg, H, Hue, L, Pipeleers, D, Van De Castele, M: **AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase.** *J. Mol. Endocrinol.* 2003, 30: 151-161.
- 25 9. Kefas, BA, Heimberg, H, Vaulont, S, Meisse, D, Hue, L, Pipeleers, D, Van De Castele, M: **AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase.** *Diabetologia* 2003, 46: 250-254.

10. Stefanelli, C, Stanic, I, Bonavita, F, Flamigni, F, Pignatti, C, Guarnieri, C, Caldarera, CM: **Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4- carboxamide ribonucleoside, a cell-permeable activator of AMP-activated protein kinase.** *Biochem. Biophys. Res. Commun.* 1998, **243**: 821-826.
11. Blazquez, C, Geelen, MJ, Velasco, G, Guzman, M: **The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes.** *FEBS Lett.* 2001, **489**: 149-153.
12. Wang, W *et al.*: **AMP-activated kinase regulates HuR subcellular localization.** *Mol. Cell. Biol.* 2002, **27**: 3425-3436.
13. Imamura, K, Ogura, T, Kishimoto, A, Kaminishi, M, Esumi, H: **Cell Cycle Regulation via p53 Phosphorylation by a 5'-AMP Activated Protein Kinase Activator, 5-Aminoimidazole- 4-Carboxamide-1-beta-d- Ribofuranoside, in a Human Hepatocellular Carcinoma Cell Line.** *Biochem. Biophys. Res. Commun.* 2001, **287**: 562-567.
14. Hawley, SA, Davison, M, Woods, A, Davies, SP, Beri, RK, Carling, D, Hardie, DG: **Characterization of the AMP-activated protein kinase kinase from rat liver, and identification of threonine-172 as the major site at which it phosphorylates and activates AMP-activated protein kinase.** *J. Biol. Chem.* 1996, **271**: 27879-27887.
15. Sutherland, CM, Hawley, SA, Stark, MJR, Hardie, DG: **Identification of Elm1p as one of three upstream kinases for the *Saccharomyces cerevisiae* SNF1 complex.** *Curr. Biol.* 2003: submitted.
16. Nath, N, McCartney, RR, Schmidt, MC: **Yeast Pak1 kinase associates with and activates Snf1.** *Mol. Cell. Biol.* 2003, **23**: 3909-3917.

17. Hawley, SA, Selbert, MA, Goldstein, EG, Edelman, AM, Carling, D, Hardie, DG: **5'-AMP activates the AMP-activated protein kinase cascade, and Ca²⁺/calmodulin the calmodulin-dependent protein kinase I cascade, via three independent mechanisms.** *J. Biol. Chem.* 1995, **270**: 27186-27191.
18. Hemminki, A *et al.*: **A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.** *Nature* 1998, **391**: 184-187.
19. Jenne, DE, Reimann, H, Nezu, J, Friedel, W, Loff, S, Jeschke, R, Muller, O, Back, W, Zimmer, M: **Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.** *Nat. Genet.* 1998, **18**: 38-43.
20. Hemminki, A: **The molecular basis and clinical aspects of Peutz-Jeghers syndrome.** *Cell. Mol. Life Sci.* 1999, **55**: 735-750.
21. Giardiello, FM, Brensinger, JD, Tersmette, AC, Goodman, SN, Petersen, GM, Booker, SV, Cruz-Correa, M, Offerhaus, JA: **Very high risk of cancer in familial Peutz-Jeghers syndrome.** *Gastroenterology* 2000, **119**: 1447-1453.
22. Boudeau, J, Sapkota, G, Alessi, DR: **LKB1, a protein kinase regulating cell proliferation and polarity.** *FEBS Lett.* 2003, **546**: 159-165.
23. Tiainen, M, Ylikorkala, A, Makela, TP: **Growth suppression by LKB1 is mediated by a G(1) cell cycle arrest.** *Proc. Natl. Acad. Sci. USA* 1999, **96**: 9248-9251.
24. Tiainen, M, Vaahtomeri, K, Ylikorkala, A, Makela, TP: **Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1).** *Hum. Mol. Genet.* 2002, **11**: 1497-1504.
25. Jishage, K *et al.*: **Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis.** *Proc. Natl. Acad. Sci. USA* 2002, **99**: 8903-8908.

26. Bardeesy, N, Sinha, M, Hezel, AF, Signoretti, S, Hathaway, NA, Sharpless, NE, Loda, M, Carrasco, DR, DePinho, RA: **Loss of the LKB1 tumour suppressor provokes intestinal polyposis but resistance to transformation.** *Nature* 2002, **419**: 162-167.
- 5 27. Miyoshi, H, Nakau, M, Ishikawa, TO, Seldin, MF, Oshima, M, Taketo, MM: **Gastrointestinal hamartomatous polyposis in LKB1 heterozygous knockout mice.** *Cancer Res.* 2002, **62**: 2261-2266.
28. Rossi, DJ *et al.*: **Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis.** *Proc. Natl. Acad. Sci. U S A* 2002, **99**:
10 12327-12332.
29. Nakau, M, Miyoshi, H, Seldin, MF, Imamura, M, Oshima, M, Taketo, MM: **Hepatocellular carcinoma caused by loss of heterozygosity in LKB1 gene knockout mice.** *Cancer Res.* 2002, **62**: 4549-4553.
30. Baas, AF, Boudeau, J, Sapkota, GP, Smit, L, Medema, R, Morrice, NA, Alessi, DR, Clevers, HC: **Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD.** *EMBO J.*
15 2003, **22**: 3062-3072.
31. Boudeau, J, Baas, AF, FDeak, M, Morrice, NA, Kieloch, A, Schutowski, M, Prescott, AR, Clevers, HC, Alessi, DR: **MO25 isoforms interact with the STE20-related pseudokinase STRAD α/β and enhance their ability to bind, activate and localise the LKB1 tumour suppressor in the cytoplasm.** *EMBO J.* 2003: submitted;
20 Example 1.
32. Corton, JM, Gillespie, JG, Hawley, SA, Hardie, DG: **5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells?** *Eur. J. Biochem.* 1995, **229**: 558-565.
25

33. Hawley, SA, Gadalla, AE, Olsen, GS, Hardie, DG: **The anti-diabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism.** *Diabetes* 2002, **51**: 2420-2425.
- 5 34. Sapkota, GP, Deak, M, Kieloch, A, Morrice, N, Goodarzi, AA, Smythe, C, Shiloh, Y, Lees-Miller, SP, Alessi, DR: **Ionizing radiation induces ataxia telangiectasia mutated kinase (ATM)-mediated phosphorylation of LKB1/STK11 at Thr-366.** *Biochem. J.* 2002, **368**: 507-516.
- 10 35. Collins, SP, Reoma, JL, Gamm, DM, Uhler, MD: **LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo.** *Biochem. J.* 2000, **345 Pt 3**: 673-680.
- 15 36. Sapkota, GP, Kieloch, A, Lizcano, JM, Lain, S, Arthur, JS, Williams, MR, Morrice, N, Deak, M, Alessi, DR: **Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth.** *J. Biol. Chem.* 2001, **276**: 19469-19482.
- 20 37. Sapkota, GP, Boudeau, J, Deak, M, Kieloch, A, Morrice, N, Alessi, DR: **Identification and characterization of four novel phosphorylation sites (Ser31, Ser325, Thr336 and Thr366) on LKB1/STK11, the protein kinase mutated in Peutz-Jeghers cancer syndrome.** *Biochem. J.* 2002, **362**: 481-490.
- 25 38. Boudeau, J, Deak, M, Lawlor, MA, Morrice, NA, Alessi, DR: **Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability.** *Biochem. J.* 2003, **370**: 849-857.

39. Alessi, DR: **Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. *Biochem. Soc. Trans.* 2001, 29: 1-14.**
- 5 40. Manning, G, Whyte, DB, Martinez, R, Hunter, T, Sudarsanam, S: **The protein kinase complement of the human genome. *Science* 2002, 298: 1912-1934.**
41. **Kinase.com** [<http://www.kinase.com/>]
42. Sugden, C, Donaghy, PG, Halford, NG, Hardie, DG: **Two SNF1-related protein kinases from spinach leaf phosphorylate and inactivate HMG-CoA reductase, nitrate reductase and sucrose phosphate synthase *in vitro*. *Plant Physiol.* 1999, 120: 257-274.**
- 10 43. Wilson, WA, Hawley, SA, Hardie, DG: **The mechanism of glucose repression/derepression in yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. *Current Biol.* 1996, 6: 1426-1434.**
- 15 44. Scott, JW, Norman, DG, Hawley, SA, Kontogiannis, L, Hardie, DG: **Protein kinase substrate recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a model substrate. *J. Mol. Biol.* 2002, 317: 309-323.**
- 20 45. Woods, A, Salt, I, Scott, J, Hardie, DG, Carling, D: **The $\alpha 1$ and $\alpha 2$ isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity *in vitro*. *FEBS Lett.* 1996, 397: 347-351.**
- 25 46. Sugden, C, Crawford, RM, Halford, NG, Hardie, DG: **Regulation of spinach SNF1-related (SnRK1) kinases by protein kinases and phosphatases is associated with phosphorylation of the T loop and is regulated by 5'-AMP. *Plant J.* 1999, 19: 1-7.**

47. Hardie, DG, Salt, IP, Davies, SP: Analysis of the role of the AMP-activated protein kinase in the response to cellular stress. *Methods Mol. Biol.* 2000, 99: 63-75.
48. Bradford, MM: A rapid and sensitive method for the quantitation
5 of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 1976, 72: 248-254.
49. Devereux, J, Haeberli, P, Smithies, O: A comprehensive set of sequence analysis programs for the VAX. *Nuc. Acids Res.* 1984, 12: 387-395.
- 10 50. **BOXSHADE** v3.21
[http://www.ch.embnet.org/software/BOX_form.html]

Example 3: Peptide substrate for LKB1

- 15 A kinase assay for LKB1 can be performed using a peptide substrate, for example using the T-loop peptide of AMPK whose sequence is

LSNMMSDGEFLRTSCGSPNRRR

- (HUMAN AMPKalpha-1 Residues 163-181 with 3 additional Arg residues
20 added to the C-terminal to enable binding to P81 paper).

- An assay may be performed as follows. Other assays using such a substrate peptide may be used, for example in a high throughput format. The standard assay (50 µl) contained: 0.3 µg of purified GST-LKB1-STRADα-
25 MO25α complex, 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 0.1% (by vol) 2-mercaptoethanol, 10mM magnesium acetate, 0.1 mM [$\gamma^{32}\text{P}$]ATP (~200 cpm/pmol) and T-loop peptide (LSNMMSDGEFLRTSCGSPRRR, 10-2000 µM). The assays were carried out for 30 min at 30°C, then terminated by

pipetting the reaction mixture onto a 1 cm square of p81 paper, which was washed with 6 changes of 250 ml of 50 mM phosphoric acid (2 min each wash), the paper washed once in 200 ml of acetone and dried. Radioactivity bound to the p81 paper was quantitated by Cherenkov counting. 1 unit of activity is the amount of enzyme that catalyses the phosphorylation of 1 nmol of peptide per minute.

The K_m for the peptide was estimated to be 1.80 ± 0.48 and the V_{max} 23.4 ± 3.5

CLAIMS

1. A method for identifying a compound for use in modulating, for example promoting, the activation or phosphorylation of AMPK (AMP-
5 activated protein kinase) or AMPK subfamily member in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example promotes, the protein kinase activity of LKB1 and (2) selecting a compound which modulates, for example promotes, the protein kinase activity of LKB1.
- 10 2. The method of claim 1 wherein the LKB1 is in a preparation with STRAD and/or MO25.
3. The method of claim 1 or 2 wherein the LKB1, STRAD or MO25 is recombinant.
4. A purified preparation comprising LKB1, STRAD and recombinant
15 MO25.
5. The preparation of claim 5 comprising recombinant LKB1.
6. The preparation of claim 4 or 5 comprising recombinant STRAD.
7. A cell capable of expressing LKB1, STRAD and overexpressed or recombinant MO25.
- 20 8. The cell of claim 7 comprising a recombinant nucleic acid encoding MO25.
9. The cell of claim 7 or 8 comprising a recombinant nucleic acid encoding LKB1.
10. The cell of any one of claims 7 to 9 comprising a recombinant nucleic
25 acid encoding STRAD.
11. A cell comprising LKB1, STRAD and overexpressed or recombinant MO25.
12. A cell according to claim 11 comprising recombinant LKB1.
13. A cell according to claim 11 or 12 comprising recombinant STRAD.

14. A cell according to any one of claims 11 to 13 wherein the cell is a cell according to any one of claims 7 to 10.
15. A method for making a preparation according to any one of claims 3 to 6 comprising the step of purifying the preparation from a cell according to any one of claims 11 to 14.
16. A preparation obtainable by the method of claim 15.
17. The preparation of any one of claims 3 to 6 or 16 wherein the LKB1:STRAD:MO25 ratios are 1:1:1.
18. The method of claim 1, 2 or 3 wherein the LKB1 is in a preparation as defined in any one of claims 3 to 6 or 17 or a preparation obtained by or obtainable by the method of claim 15 or in a cell as defined in any one of claims 7 to 14.
19. The preparation or method of any one of claims 1 to 6, 15 to 18 wherein the preparation comprises a complex comprising the LKB1, STRAD and MO25.
20. A method for identifying a compound for modulating cellular LKB1 activity, the method comprising the steps of (1) determining whether a test compound modulates the LKB1 protein kinase activity of a preparation or complex as defined in any one of claims 3 to 6, 16, 17 or 19 claim 19 or in a cell as defined in any one of claims 7 to 14 and (2) selecting a compound which modulates the said LKB1 protein kinase activity.
21. The method of claim 1 or claim 20 wherein the LKB1 protein kinase activity is measured using AMPK or AMPK subfamily member or a fragment either thereof as the substrate.
22. A kit of parts comprising LKB1 or a recombinant polynucleotide encoding LKB1, STRAD or a recombinant polynucleotide encoding STRAD, and MO25 or a recombinant polynucleotide encoding MO25.

23. A kit of parts comprising (1) AMPK or AMPK subfamily member, or recombinant polynucleotide encoding AMPK or AMPK subfamily member or a fragment thereof and (2) a kit of parts as defined in claim 22 or a preparation or complex as defined in any one of claims 3 to 6, 16, 17 or 19 claim 19 or a cell as defined in any one of claims 7 to 14.
24. A method for overexpressing LKB1 comprising the steps of (1) selecting a cell type in which to overexpress LKB1, comprising the step of determining whether the cell type is one that expresses STRAD and/or MO25 (2) overexpressing LKB1 in the selected cell type.
25. A method for preparing LKB1 comprising the steps of (1) overexpressing LKB1 in a cell using a method according to claim 24 and (2) preparing LKB1 from the cell.
26. A method for identifying a putative binding partner for MO25 comprising the steps of (1) providing an amino acid sequence of at least the C-terminal three amino acids of a test putative binding partner (2) selecting a putative binding partner having the C-terminal amino acid sequence Trp-Glu/Asp-Phe.
27. The method of claim 26 further comprising the step of determining that the selected putative binding partner binds to MO25.
28. A method for identifying a genetic difference associated with PJS (Peutz-Jeghers Syndrome) comprising the steps of (1) investigating the sequence of a gene encoding a STRAD or MO25 isoform in at least one patient having PJS (2) identifying any difference between the said patient sequence and equivalent sequence from an individual without PJS.
29. A method for determining whether an individual is susceptible to PJS comprising the steps of determining whether the test individual has a genetic difference identified as associated with PJS by a method according to claim 28.


30. A method for identifying a compound which activates AMPK or AMPK subfamily member by a similar mechanism to metformin or phenformin or AICA riboside in which the effect of a test compound on the activation of AMPK or AMPK subfamily member by a preparation or complex as defined in any one of claims 3 to 6, 16, 17 or 19 claim 19 or a cell as defined in any one of claims 7 to 14 is compared with the effect of metformin or phenformin or AICA riboside on the activation of AMPK or AMPK subfamily member and a compound with a similar effect is selected.
31. Use of an AMPK subfamily member or polynucleotide encoding an AMPK subfamily member in the manufacture of a medicament for treating diabetes or obesity

ABSTRACT

A method for identifying a compound for use in modulating, for example promoting, the activation or phosphorylation of AMPK (AMP-activated
5 protein kinase) or AMPK subfamily member in a cell, the method comprising the steps of (1) determining whether a test compound modulates, for example promotes, the protein kinase activity of LKB1 and (2) selecting a compound which modulates, for example promotes, the protein kinase activity of LKB1. The protein kinase activity may be tested
10 using AMPK or an AMPK subfamily member, or a peptide encompassing the T-loop region of AMPK or an AMPK subfamily member.

The LKB1 may be in a preparation or complex with STRAD and/or MO25, which has much greater kinase activity than LKB1 in the absence of these
15 accessory proteins. The LKB1, STRAD or MO25 may be recombinant.

Figure 3.



B

	Protein name	Peptide matches	% sequence coverage	NCBI gi number
■	Hsp90	15/44	30%	20149594
▲	Flag-LKB1	14/46	35%	7106425
●	Cdc37	31/72	59%	5901922
◆	STRADα	11/80	34%	12060855
*	MO25α	17/37	47%	7706481

C




Figure 1

1/20




Figure 2




Figure 3

3/20




Figure 4
4/20




Figure 5




Figure 6

6/20




Figure 7




Figure 8



hSTRAD α 1 MSFLVSKDEIRRRVSEKFFIVEGLRDLELFEQPPGDTRRKTNDASSESISASFQEVMS
hSTRAD β 1 -----MSLDDCFCSRTOVESLRPEK-----QSETSIHQYLVDEPTLSWSRPSTRASEV
hSPAK 1 -----MAEPSPGSPVHVQLPQQAAPVTAAAAAPAAATAAPAPAPAPAPAPAPAPAAQAV
hOSR1 1 -----MSEDSAL

hSTRAD α 61 SELPEGGCYELLTVIGKGFEDLMTVNLARYKPTGEYVTVRRINLEACSNEMVTFLQGEFH
hSTRAD β 50 LCSTNVSHYELQVEIGRGEDNLTSVHLARHTPTGTLVTIKITNLENCNEERLKALQKAWI
hSPAK 57 GWPTICRDAYELQEVIGSG--ATAVVQAALCKPRQERVAIKRINLEKCQTSMDLELK-EIQ
hOSR1 9 PWSINRDDYELQEVIGSG--ATAVVQAAYCAPKKEIVAIAIKRINLEKCQTSMDLELK-EIQ

hSTRAD α 121 VSKLFNHPNIVPYRAIFADNELWVTSFMAYGSAKDITCTHFMDG-----MNELATAY
hSTRAD β 110 LSHFFRHPNITTYTVFTVGSWLWVSPFMAYGSASQARTYFPEG-----MSEHTRN
hSPAK 114 AMSQCSHPNVITYTSEFVVKDELWVMKLLSGGSMLDIKYIVNRGEHKNGVLEEAATAT
hOSR1 66 AMSQCHHPNIVSYTSEFVVKDELWVMKLLSGGSVLDIKHIVAKGEHKSGLLESTIAT

hSTRAD α 175 ILQGVKALDYIHEMGYVHRSVKASHILISVDGKVYLSGLRSNLSMISHGQRQRVVDHFP
hSTRAD β 164 ILFGAIVRGLNYLHONGCIHRSVKASHILISGDGLVILSGLSHLHSLVKHGQRHRAVDFF
hSPAK 174 ILKEVLEGLDYLHNGQIHRDKAGNILLGEDGSVQIADFGVSAFLATGGDVTR--NKVR
hOSR1 126 ILREVLEGLNYLHNGQIHRDVKAGNILLGEDGSVQIADFGVSAFLATGGDITR--NKVR

hSTRAD α 235 KYSVKVLPWLSPEVFCNLEGYDAKSDISVGITACELANGHVPEKDMPATQMLLEKLNQ
hSTRAD β 224 QFSTSVQPWLSPEVFCNLEGYVKSDDISVGITACELASGVQVPMQDMHRTQMLLQKLKG
hSPAK 232 KTFVGTFCWMAPEVMEQ--VRGYDFKADISVGITAEELATGAAPVHKYPPMKVLLTLQN
hOSR1 184 KTFVGTFCWMAPEVMEQ--VRGYDFKADISVGITAEELATGAAPVHKYPPMKVLLTLQN

hSTRAD α 295 ---TVP-----CLL-DTSTIPAEELTMSPSRSVANSGL-SDSL
hSTRAD β 284 -PPYSP-----L--DISIFPQSESRTMKNSQSGVDSGIGESYL
hSPAK 291 DPPTLETGVEDKEMKKYKGSFRKSLCLQKDPSKRPTAAELKCKFFQKAKNR-BLL
hOSR1 243 DPPSLETGVQDKEMKKYKGSFRKSLCLQKDEKRPTAAELRHKFFQKAKNK-EELQ

hSTRAD α 328 TTSTPRPSNGDWPSHPYHRT--FSPFPHFVEQCLQRPDARPSASTLLNHSFFKQIKRR
hSTRAD β 318 VSSGTHTVNSDRLHTPSSKT--FSPAFFSLVQLCLQDPEKRPSASSLLSHVFFKQMKEE
hSPAK 350 EKLLTRTPIAQRAKKVRRVPGSSGRLHKTEDCGWEWSDDDEKSEEGKAAFSQEKSRR
hOSR1 302 EKLLQRAPTISERAKVRRVPGSSGRLHKTEDCGWEWSDDDEFDEESEEGKAALSQLRSPR



hSTRAD α 386 ASK-----APPELLRP-----VTPITNF
hSTRAD β 376 SQD-----SILSLRP-----PAY
hSPAK 410 VKE--ENPEIAVSAS-----IPEQIQS-----TSVHDSQGPANEDY
hOSR1 362 VKESISNSELPFTTDPVGTLLQPEQISAHLPPQAGQIATQPTQMSLPPTAEPAKTAQAL

hSTRAD α 404 EGSQ-S----QDHSGLFGLVTNLEEEVDDNEF-----
hSTRAD β 389 NKPSIS--LPPVLPWTEPECDFPDEKDSYNEF-----
hSPAK 447 REAS-S----CAVNLVLRRLNSKELNDIREFTPGRDTAAGVSQELFSAGLVDGHDVVI
hOSR1 422 SSQSGSQETKIPISLVLRRLNSKELNDIREFTPGRDTAAGVSQELFSAGLVDGHDVVI

hSTRAD α -----
hSTRAD β -----
hSPAK 502 VAANLQKIVDEPKALKITFKLASGCGSIPDEVKLIGFAQLSIS
hOSR1 482 VAANLQKIVDEPQSNRSITFKLASGVEGSIIPDEGKLIGFAQLSIS

Supplementary figure 10

10/20




Supplementary figure 2




Hawley et al Figure 1

Tos3	11	..LPRSSLLYNNASNSSSSRIKETRKVKLLYNPLTKR.....Q...ILNNFEILATLGNQ
Pak1	94	..TPTTTSSFCSSGSSKNKVKETNRISLTYDPVSKR.....K...VLNTYEIIKELGHGQ
CaMKK β	121	CICPSLPYSPVSSPQSSPRLPRRPTVESHHVSITGM.....QDCVQLNQYTLKDEIGKGS
LKB1	7	QQLGMFTEGELMSVGMDFIHRIDSTEVYQP..RR.....KRAKLIGKYLMDLLGEGS
Elm1	39	TSSFSSFSQOKPTYSTIIGENIHTILDEIRPYVKKITVSDQDKKTINQYTLGVSAGSGQ
consensus	121	p ss s s ss rik tv l y pltkr q ilnny i lg Gq
Tos3	61	YGKVKLARDLGTGALVAIKILNRFEKRS....GYSL.....QLKV.EN.....
Pak1	144	HGKVKLARDILSKQLVAIKIVDRHEKKQRKFFTFIK.....SSKISEN.....
CaMKK β	176	YGVVKLAYNENDNTYYAMKVLK..KKLIRQAGFPR.....RPPPRGTRPAPGGCIQP
LKB1	60	YGKVKEVLDSETLCRRRAVKILK..KKLRR.....I
Elm1	99	FGYVRKAYSSSTLGKVVAVKIIPKKPWNAAQQYSVNQVMRQIQLWKSCKGKITTNMSGNEAMR
consensus	181	yGkVkla d t lvAiKil k kk k y k
Tos3	99PRVQEIIEVMKRCHHE.NVVELYEILNDPESTKVYLVLVEYCSRGVPVKWCPCENKMEI
Pak1	187DKIKREIAIMKKCHHK.HVVQLIEVLDDLKSRKIYLVLEYCSRGVEVKWCPPDCMES
CaMKK β	227	RGPIEQVYQEIAILKKLDHP.NVVKLVEVLDDPNEDHLYMVFELVNQGPV.....MEV
LKB1	89	PNGEANVKKEIQLLRRLRHK.NVIQLVDVLYNEEKQKMYMMEYC.....VCGMQEM.L
Elm1	159	LMNIEKCRWEIFAASRLRNNVHIVRLIECLDSPFSESIWIVTNWCSLQWKRDDDEDI
consensus	241	drvK EI vmkrlhh nvv LievLddp skvylVleycs g v wc mei
Tos3	154	.KAVGPSILTFQO....SRKVVLVDVSGLEYLHSGGITHRDIKPSNLLISSNGTV.KISD
Pak1	242	.DAKGPSLLSFQE....TREILRGVVLGLEYLHYQGIIHRDIKPANLLISGDGTV.KISD
CaMKK β	279	.PTLKP..LSEDQ....ARFYFQDLIKGIEYLHYQKIIHRDIKPSNLLVGEDGHI.KIAD
LKB1	141	.DSVPEKRFVQC....AHGYFCQLIDGLEYLHSGGIVHKDIKPGNLLLTGGTL.KISD
Elm1	219	LPQWKKIVISNCSVSTFAKKILEDMTKGLEYLHSGGCIHRDIKPSNILLDEEEKVAKLSD
consensus	301	v p ils q ar vv dvv GLEYLHsQgiiHrDIKPsNllis dgtv KisD
Tos3	208	FG..VAM.STATGSTNIQSSHEQLLKSRLGTPAFFAPELCSTEKEY.....
Pak1	296	FG..VSLAASSTNSSDSSSLELELAKTVGTPAFFAPEMCLGEDAFTRYNLTKENLFRG
CaMKK β	331	FG..V.....SNEFKGS..DALLSNTVGTAPAFMAPESLS.....ETRKIFSG
LKB1	195	LG..VAEALHPFAADDTCTRSQ.....GSPAFQPPEIANGLDTFE.....
Elm1	279	FGSCIFTPQSLPFSDANFEDCFQRELNKIVGTAPAFIAPELCHLGNSKRDFVTD.....
consensus	361	fG v t s d s l r vGtPAF aPElc y
Tos3	252	SC.SSAIDIWSLGVTTIYCLLFGKLPFNANSGLLELFDISIINKPLEFPSYEEMLNATSGIT
Pak1	354	SCISFMIDIWAVGVTLYCLLFGMLPFFSDFELKLFKIVNDPLKFPTFKEIQSNKVS
CaMKK β	369	K...ALDVWAMGVTLYCFVFGQCPFMDERIMCLHSHKIKSQALEFPDQPDIA.....
LKB1	233	...GFKVDIWSAGVTLYNITTGLYPFEGDNIYKLFENIGKGSYAIP.....
Elm1	332	...GFKLDIWSLGVTTLYCLLYNELPFFGENEFETYHKIIEVSLSSKINGNTLNDLVIKRL
consensus	421	f iDiWslGVTTLYcllfg lPF ad l lfdkIi l fp em
Tos3	311	M.EEYT...DAKDLLKKLLQKDPDKRIKLADIKVHPFMC....HYGKSDAASVL...TN
Pak1	414	CEEEYE...MAKDLLLLKLLKLEKNPQKRMTIPAICKHPFVS.WDFDHVPENDEKLLS...SV
CaMKK β	417E...DLKDLITRMLDKNPESRIVVPEIKLHPVWTRHGAEPLPSEDENCTLVEVTE
LKB1	276	.GDCGP...PLSDLKGMLEYEPAKRFSIRQIRQHSWFRK...KHPPAEAPVPIPPSPDT
Elm1	389	LEKDVTLRISIQDLVKVLSRDQPIDSRNHSQISSSS.VNPVRNEGVPVRRFFGRLLTKKKG
consensus	481	ee lkDLlkkllleknP kri l Ik hpfv dh p d vl t
Tos3	359	LETFHELKVSPP.....SSCKRVELVSLPVNSSFASLDSVYMFENFDHNNLRTGADRNS
Pak1	467	LE..QKLRF.....QCNOTDQFE.PISISKHELKNAV.....SGVGKKIKESV
CaMKK β	469	EEVENSVKHIPSLATVILVKTMIKRSGFNGPFEGSRREERSLSAPGNLLTKQGSEDNLQG
LKB1	329	KDRWRSMTVVPYLEDLHGADEDEDLFDIEDDIYTDQFTVPGQVPEEEASHNGQRRGLPK
Elm1	448	KKTSGKGKDKVLVSATSKVTFSIHIDEEDPKECFSTTVLRSSPDSSDYCSSLGEEAIQVT
consensus	541	e lk p l rve pv s lks s lg


Hawley et al Figure 2




A) Activity in supernatant




C) Activity in pellet




B) Immunoprecipitation of polypeptides




D) Immunoblotting of pellets




A) Activation of AMPK α 1 catalytic domain by LKB1




B) Phosphorylation of AMPK α 1 catalytic domain by LKB1




Hawley et al Figure 5/6



Hawley et al Figure 6/7



Hawley et al Figure 7 δ




18/20

Hawley et al Figure 8¹⁹

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

02/02



$K_m: 1.80 \pm 0.48$

$V_{max}: 23.43 \pm 3.51 \text{ U/mg}$

Figure 20

PCT/GB2004/003096

